Protein-Protein Interactions of the Human Iron Sulfur Cluster Biosynthesis Complex by Levy, Michaella J
  
 
 
PROTEIN-PROTEIN INTERACTIONS OF THE HUMAN IRON SULFUR CLUSTER 
BIOSYNTHESIS COMPLEX 
 
A Dissertation 
by 
MICHAELLA JANE LEVY 
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,  David Barondeau 
Committee Members, Marcetta Y. Darensbourg 
 Margaret E. Glasner 
 David H. Russell 
Head of Department, David H. Russell 
 
 
August 2014 
 
Major Subject: Chemistry 
 
Copyright 2014 Michaella Levy
 ii 
 
ABSTRACT 
 
Iron sulfur (Fe-S) clusters are integral cofactors responsible for a number of 
cellular processes including electron transfer, catalyzing substrate turnover, sensing 
small molecules, and regulating gene expression or enzymatic activity. Elaborate multi-
component systems have evolved to protect organism from the toxic effects of free iron 
and sulfide ions while promoting the efficient biosynthesis of these cofactors. 
Previously, our lab discovered the human cysteine desulfurase complex (NFS1-ISD11, 
named SD) and the Fe-S assembly scaffold protein ISCU2 form a low activity Fe-S 
assembly complex (named SDU) that can be activated by the allosteric activator frataxin 
(FXN) to generate the high activity SDUF Fe-S assembly complex. Importantly, 
mutations in FXN result in the neurodegenerative disease Friedreich’s Ataxia (FRDA), 
whereas mutations in ISCU2 lead to a disease characterized by myopathy with exercise 
intolerance.  
The goals of this dissertation were to provide structural details for protein-protein 
interactions in the human SDUF complex, contribute to understanding how FXN binds 
and activates the assembly complex, and define how a clinical ISCU2 variant was 
compromised in Fe-S assembly activity.  To address these questions, a multidisciplinary 
approach was initiated that included anaerobic biochemistry and kinetic assays, 
fluorophore incorporation for anisotropy measurements, and chemical modifications 
coupled to mass spectrometry experiments.  First, protein interfaces were probed by 
hydroxyl radical footprinting experiments where the SD, SDU, and SDUF complexes 
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were exposed to different does of synchrotron radiation (generating hydroxyl radicals) 
and the resulting modified proteins were proteolytically digested and analyzed by 
MALDI mass spectrometry.  These experiments revealed that ISCU2 binding to the SD 
complex results in a decrease in modification kinetics to for regions of ISCU2 near the 
N-terminus. Consistent with this assignment, kinetic assays revealed that the clinical 
ISCU2 variant, which has a mutation near the N-terminus, exhibits cysteine desulfurase 
and Fe-S assembly activities similar to native ISCU2, but compromised binding affinity 
to the assembly complex. Next, hydroxyl radical footprinting experiments revealed that 
FXN binding to the SDU complex resulted in the C-terminal α-helix of ISCU2 becoming 
more protected and suggested specific interactions associated with FXN activation.  
Next, fluorescence anisotropy experiments under different experimental conditions 
revealed both determinants for FXN binding and that the FRDA variant has 
compromised binding affinity to the SDU complex. Finally, this activation model was 
tested and supported by mutagenesis and binding studies that indicated residues in this 
C-terminal α-helix of ISCU2 interacts with residues on the β-sheet region of FXN, which 
are associated with FRDA. Together, these studies reveal details of the protein-protein 
interactions and function of the human SDUF complex that have implications for human 
disease. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Iron sulfur (Fe-S) clusters are integrals cofactors found in most, if not all, 
organisms and are commonly found with stoichiometries such as a rhombic 2Fe-2S, a 
3Fe-4S, or a cubane 4Fe-4S (Figure 1-1, A-C).1-3  Fe-S clusters play a critical role in 
many important biological processes including electron transfer or catalysis due to their 
ability to exist in multiple redox states. For example, 2Fe-2S clusters are found in 
proteins required for DNA repair,4 gene regulation,5 post-translational modifications,6 
and also in the biosynthesis of other iron containing proteins.7 Proteins requiring 4Fe-4S 
clusters function in respiration and the tricarboxylic acid cycle among other roles in E. 
coli.1, 8 Additionally, some clusters are required only for structural stability of proteins.1 
The functional properties of these clusters are tuned by their location, solvent accessible 
or buried in the protein, and also the characteristics of the residues that surround the Fe-
S cluster. Other configurations have also been observed for highly specialized functions 
such as the complex [8Fe-8S] P-cluster in nitrogenase (Figure 1-1D) or systems in which 
a [4Fe-4S] cluster is linked to a nickel center (acetyl-CoA synthase), a siroheme (sulfite 
reductase), or a di-iron cluster ([FeFe]-hydrogenase).9 
 2 
 
 
Figure 1-1. Common Fe-S cluster forms found in biological systems include the: A.) 
2Fe-2S cluster; B.) 3Fe-4S cluster; C.) cubane 4Fe-4S cluster; and D.) 8Fe-8S cluster 
from nitrogenase. The iron atoms are shown in red and the sulfur atoms are shown in 
yellow. Reprinted with permission from Annu. Rev. Biochem., 74:247-281. Copyright 
2005 Annual Reviews.9 
 
 
It appears that prokaryotic organisms took advantage of the properties of iron and 
sulfur to perform cellular tasks in a reducing, anaerobic environment.10-16 In fact, the 
Holm’s group and others have demonstrated that the common biological forms of Fe-S 
clusters can be self-assembled from iron and sulfide in solution.17 Unlike the early 
reducing environment in which there were high levels of ferrous iron and hydrosulfide 
ion, after the Great Oxidation Event both reagents became limited. As a consequence, 
bacteria developed three separate Fe-S assembly systems, the nitrogen fixation (NIF), 
mobilization of sulfur (SUF), and the iron-sulfur cluster assembly (ISC) pathways.18-22 
These Fe-S assembly systems have evolved to not only sequester and protect the cell 
from the potentially toxic effects of free iron and sulfide, but also synthesize and deliver 
different forms of Fe-S clusters to the appropriate apo targets.11  Eukaryotic Fe-S cluster 
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assembly pathways that are found in organelles appear to have evolved from these 
bacterial systems (Figure 1-2).22, 23 For example, the Fe-S assembly machinery inside 
plant and algae plastids is analogous to the SUF machinery, whereas mitochondria 
contain Fe-S cluster machinery with homology to the ISC system. Eukaryotes also 
contain an additional pathway termed the cytosolic iron sulfur cluster assembly (CIA), 
which can deliver Fe-S clusters to appropriate proteins in the cytosol and the nucleus.22 
The CIA pathway is unique in that it has no prokaryotic analog and does not appear to 
contain typical assembly components such as a cysteine desulfurase or Fe-S scaffold 
protein (see below). 
 
 
 
 
Figure 1-2. Iron sulfur cluster assembly pathways. Reprinted with permission from 
Annu. Rev. Cell Dev.Biol, 22:457-486. Copyright 2006 Annual Reviews.22 
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Fe-S ASSEMBLY PATHWAYS IN PROKARYOTES 
The best studied iron sulfur cluster assembly system is likely the ISC pathway 
from E. coli. The ISC operon from E. coli (Figure 1-3)24 contains the genes thought to be 
critical for Fe-S assembly, and many of the assembly proteins have functional analogs in 
the NIF and SUF systems. The cysteine desulfurase (IscS in Figure 1-3) is a PLP-
dependent enzyme that converts cysteine to alanine and forms a transient persulfide 
intermediate with a cysteine on the mobile loop (Figure 1-4).9, 25, 26 
 
 
 
 
 
 
Figure 1-3. ISC operon from E. coli. Adapted with permission from Current Opinion in 
Chemical Biology, 7:166-173. Copyright 2003 Elsevier Science Ltd.24 
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Figure 1-4. Cysteine desulfurase catalyzed sulfur carbon bond cleavage of a PLP-
substrate adduct to form a cysteine bound persulfide. Reprinted with permission from 
Annu. Rev. Biochem., 74:247-281. Copyright 2005 Annual Reviews.9 
 
 
 
The cysteine desulfurase transfers the sulfur to the second component of the 
system, the Fe-S cluster assembly scaffold protein.  The scaffold protein (IscU, Figure 1-
3) combines the sulfur atoms with iron and electrons to synthesize Fe-S clusters.25 It has 
been shown that the scaffold can assemble a single [2Fe-2S]2+ on a monomer of the 
scaffold that can be reductively coupled to form a [4Fe-4S]2+ cluster, which is thought to 
bridge the subunits in a homodimeric IscU species.9, 27-29 The [4Fe-4S]2+ cluster can be 
oxidized back to the [2Fe-2S]2+ upon exposure to O2.
28 
Crystal structures of the E. coli IscS homodimeric30 and IscS-IscU 
homotetramer31 species reveal protein-protein interactions and provide a basis for the 
development of testable functional models. The crystal structure of IscS-IscU shows that 
the C-terminus of each subunit of the of IscS dimer interacts with the N-terminus of a 
IscU molecule to create an elongated S-shaped complex (Figure 1-5).31 A crystal 
structure was also recently determined for the Archaeoglobus fulgidus (A. fulgidus) IscS-
IscU complex that contains a [2Fe-2S].32 Interestingly, the three conserved IscU 
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cysteines along with mobile loop cysteine of IscS ligated the Fe-S cluster. The D37A 
IscU mutant (discussed below), which is thought to stabilize the labile Fe-S cluster 
species and also form a tighter protein complex with IscS, was used for both of the IscS-
IscU crystallographic studies. Gel filtration studies also support a heterotetrameric IscS-
IscU complex in solution,33 whereas the molecular envelope from small angle X-ray 
scattering (SAXS) curves suggest a solution structure consistent with the elongated S-
shaped observed in the crystal structure.34 
The co-crystal of the E. coli IscS-IscU has brought into question what oligomeric 
state of IscU is the biologically relevant form for cluster assembly and transfer. Johnson 
and co-workers have observed the formation of a [4Fe-4S]2+ cluster that bridges a dimer 
interface of two IscU monomers from A. vinelandii.27, 28Based on this result, most Fe-S 
assembly models invoke a dimeric IscU species that interacts with chaperones for cluster 
transfer to apo target proteins. However, in the IscS-IscU crystal structure each molecule 
of the IscS dimer interacts with a single monomer of IscU. It will therefore be critical to 
determine if the scaffold protein is capable of forming a IscU dimer when bound to IscS, 
if IscU dissociates from the cysteine desulfurase after Fe-S cluster assembly but prior to 
cluster transfer, or if the dimeric form of IscU is not relevant for cluster transfer (see 
cluster transfer models below).  
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Figure 1-5. Cartoon model of the E. coli IscS-IscU protein complex based on the crystal 
structure (PDB code: 3LVL). The IscS dimer is shown in yellow and the IscU molecules 
are shown in blue. The PLP-cofactor is shown in magenta.  
 
 
 
NMR studies of E. coli IscU indicate an equilibrium mixture between two 
conformational states, an ordered and a dynamically, disordered state that interconvert 
on the second time scale.35  Determination of the NMR structure for the ordered state 
revealed a similar conformation to that of the Zn2+ bound IscU from Haemophilus 
influenzaei
36 and the IscU conformation found in the IscS-IscU complex structures.31 
Additionally, NMR studies showed that the D39A (E. coli numbering) IscU mutation, 
which is known to bind a Fe-S cluster tighter than wild-type IscU,37-39 is primarily in the 
ordered state (Figure 1-6).35Consistent with this idea, circular dichroism (CD) 
measurements as a function of temperature revealed that mutations at position 39 
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(including D39A, D39L and D39V but not D39G) increased the thermal stability of 
IscU.40 Three additional mutations to IscU were discovered that favored the ordered state 
(N90A, S107A, and E111A) and two that favored the disordered state (K89A and N90D) 
(Figure 1-6).35Interestingly, these NMR studies suggested that IscS preferentially binds 
and stabilizes IscU in the disordered state.35  These results directly contradict previous 
experiments that indicate the D37A variant, which exhibits the ordered conformation, 
increases the binding affinity of IscS for IscU.35 
 
 
 
Figure 1-6. The crystal structure of E. coli IscU is shown highlighting the residues that 
are known to affect the protein stability by NMR.  The active site cysteine residues are 
highlighted in cyan (C37, C63, C106). The residues that favored the ordered state of 
IscU are shown in magenta (D39, N90, S107, E111) and the residue that favored the 
disordered state is shown in orange (K89). PDB code 3LVL. 
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The iron donor and reducing electron source for cluster assembly have been 
widely debated and still have not been determined.  In prokaryotes, IscA has been 
hypothesized to be an alternate scaffold to IscU41, 42 or the iron donor for Fe-S cluster 
assembly43, 44 due to its ability to bind Fe2+ and transfer the Fe2+ to IscU.45  In 
eukaryotes, it has been hypothesized that frataxin (FXN) serves as the iron donor46 and 
that a homolog of IscA is part of a three protein complex that is involved downstream of 
the chaperones and functions in delivering Fe-S clusters to a subset of [4Fe-4S]-
containing targets.47  A general scheme for the assembly and transfer of Fe-S clusters is 
shown in Figure 1-7.33, 47 
 
 
 
Figure 1-7. A cartoon representation of the minimum requirements for the general 
assembly and transfer of Fe-S clusters is shown. Reprinted with permission from Nature, 
460:831-838. Copyright 2009 Macmillan Publishers Limited.47 
 
 
 
After cluster assembly on IscU, the chaperones HscA and HscB are responsible 
for accelerating the transfer of intact Fe-S clusters to apo targets in E. coli in an ATP 
dependent manner.48, 49 NMR experiments reveal that the DNA J-like protein HscB 
interacts with IscU through residues M31, V32, V40, K42, L43, K59, E111, D112, and 
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K11550 and recruits and facilitates interactions with HscA.48 Biophysical and functional 
studies reveal that HscA binds to the conserved LPPVK motif on IscU and that these 
IscU residues have no secondary structure when bound to HscA.51-54   A model of cluster 
assembly and transfer has been proposed by Vickery et al (Figure 1-8).48 
 
 
 
Figure 1-8. The proposed mechanism of cluster transfer from holo-IscU (red) to apo 
targets by the chaperones HscA (dark blue) and HscB (cyan) is shown with a dimer 
model of IscU. Reprinted with permission from Biochemistry 48:12795-12801. 
Copyright 2008 American Chemical Society.48 
 
 
 
In this model, holo-IscU is recruited by HscB prior to binding the T-state of 
HscA that has ATP bound.  Upon the hydrolysis of ATP to ADP, HscB is released and 
HscA undergoes a conformational change to the R-state. The HscA/holo-IscU in the R-
state can then bind ATP causing the HscA to convert back to the T-state prior to IscU 
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being released for delivery of the Fe-S cluster to apo target proteins.  Upon IscU release, 
the ATP bound HscA is returned to the T-state to accept another holo-IscU molecule.48  
This model presumes that IscU dissociates from IscS after cluster assembly and interacts 
with HscB as a homodimeric species. This hypothesis has yet to be evaluated. 
 
Fe-S CLUSTER ASSEMBLY IN HUMANS 
 The prokaryotic and mitochondrial eukaryotic Fe-S cluster assembly machinery 
appears to have a common ancestor that has diverged over time.23 In mitochondria, iron 
sulfur clusters are assembled and delivered to targets by the ISC machinery.23, 55, 56  
Additional machinery exists in the cytosol, aptly named the cytosolic iron-sulfur 
assembly pathway (CIA), which is responsible for the assembly and transfer of Fe-S 
clusters (Figure 1-9).11, 57-59  The physical interactions between the CIA and ISC 
pathways are not well understood.  
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Figure 1-9. A model is shown of proteins in eukaryotic mitochondria and cytosol which 
are involved in Fe-S cluster assembly.  Reprinted with permission from Trends in 
Endocrinology and Metabolism, 21:302-314. Copyright 2010 Cell Press.11 
 
 
 The human mitochondrial Fe-S assembly pathway appears to require four 
proteins, the cysteine desulfurase, NFS1, ISD11, the scaffold protein ISCU2, and FXN 
to efficiently synthesize Fe-S clusters.33  The human mitochondrial Fe-S cluster 
assembly complex builds sequentially from the starting complex of NFS1/ISD11 (SD) 
which is unable to assemble Fe-S clusters. NFS1 in eukaryotes is the homolog to 
bacterial IscS proteins, which share an approximate 59% sequence identity to the E. coli 
IscS.  Eukaryotic NFS1 co-purifies with ISD11, a small co-protein with which is 
hypothesized to activate NFS160 and is required for the stability and solubility of 
NFS1.61-63  ISCU2 binding the SD complex forms the SDU complex, whereas binding 
both ISCU2 and FXN yields the SDUF complex. The SD, SDU, and SDUF complexes 
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were observed as distinct species by gel filtration chromatography indicating that these 
complexes are not made up of just dynamic or transient interactions and those stable 
assembly complexes can be isolated. The SDUF complex produced a slower migrating 
band on native gel electrophoresis and migrated with an estimated molecular weight of 
190 kDa on a size exclusion column that suggests a stoichiometry of approximately 
α2β2γ2δ2.
33, 64 
The role of the cysteine desulfurase is to provide sulfur for Fe-S cluster 
biosynthesis by using a PLP cofactor to convert free cysteine into alanine (Figure 1-4), 
create a transient persulfide bound to a mobile loop, and then transfer the sulfur to the 
scaffold protein.9  The activity of the cysteine desulfurase in the SD, SDU or SDUF 
complexes can be assessed by an assay modified from Siegel.65 The persulfide species is 
reductively cleaved by DTT to release inorganic sulfide into solution, the released 
sulfide is reacted with N, N’-diphenyl-p-phenylenediamine (DPD), and the formation of 
methylene blue is quantitated using the extinction coefficient at 670 nm.65 The SDUF 
complex has increased cysteine desulfurase activity compared to SD or SDU and the 
activity can be further increased by the addition of Fe2+.33 Additionally, the SDUF 
complex has increased Fe-S assembly activity compared to the SDU complex in an assay 
that monitors the increase in absorbance at 456nm, which is characteristic of [2Fe-2S] 
clusters.33 Together these experiments suggest that FXN is an activator of the Fe-S 
assembly complex and that FXN may facilitate sulfur transfer from NFS1 to ISCU2.33 
A scheme was proposed to explain the FXN based activation of the SDU 
complex.66  In this scheme, the SDU complex can react with L-cysteine to form alanine 
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and a persulfide species (Figure 1-10, the persulfide sulfur is labeled red and attached to 
NFS1 label of S of the SDU complex). In the absence of FXN, the primary fate of the 
persulfide on NFS is the generation of sulfide through DTT-mediated cleavage (Figure 
1-10, path 1). FXN binding is proposed to facilitate sulfur transfer from the persulfide on 
NFS1 to form a persulfide species on ISCU2 (Figure 1-10, path 2). The persulfide 
species on ISCU2 can then be reductively cleaved by DTT (Figure 1-10, path 3) or, in 
the presence of Fe2+ and an electron source, synthesize Fe-S clusters (Figure 1-10, path 
4).66 According to this model, the FXN-dependent acceleration of the cysteine 
desulfurase reaction is due to faster cleavage of the persulfide bound to ISCU2 (Figure 
1-10, path 3) than the persulfide bound to NFS1 (Figure 1-10, path 1). In addition, an 
FXN-defendant conformational change could increase the access of the NFS1 persulfide 
to DTT and lead to an increased cleavage of the persulfide bound to NFS1 (Figure 1-10, 
path 1). 
 
 
 
 
 
 15 
 
 
Figure 1-10. A hypothesized model of the fate of the persulfide on NFS1 to form the Fe-
S cluster on ISCU2 is shown. The sulfur atom from cysteine that becomes the persulfide 
on the mobile loop of NFS1 is shown in red. Adapted with permission from 
Biochemistry 50:6478-6487.Copyright 2011 American Chemical Society.66 
 
 
This scheme predicts that mutation of the sulfur acceptor on ISCU2 would 
eliminate the FXN-based activation of the cysteine desulfurase activity. Mutation and 
radiolabeling studies show that ISCU2 residue C104 (human numbering) is critical for 
this activation and sulfur transfer.67 The identification of this cysteine as the sulfur 
acceptor was unexpected as this cysteine is located on a somewhat buried α-helix and is 
furthest from the mobile loop on NFS1 that contains the persulfide (Figure 1-6, C106 in 
E. coli numbering).  Therefore, ISCU2 was proposed to undergo a conformational 
change upon FXN binding to position C104 to accept the sulfur from NFS1.67 
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Recently, a mutation on the scaffold has been identified at position M107I (yeast 
numbering) that is able to restore Fe-S cluster biosynthesis for a frataxin knockout strain 
of Saccharomyces cerevisiae.68 The corresponding mutation (M106I, human numbering) 
was introduced into ISCU2 and the SDUM106I complex exhibited 12-fold higher cysteine 
desulfurase and 3-fold higher Fe-S assembly activity than the wild-type SDU complex.67  
Thus, the human SDU complex with this ISCU2 mutant did not require the same level of 
FXN-based activation, consistent with the yeast frataxin bypass phenotype. This result is 
consistent with a pre-equilibrium model in which the inactive form is more stable than 
the active form, the role of frataxin is to bind and stabilize the active form, and that the 
M106I variant shifts the equilibrium similar to FXN binding (Figure 1-11). This model 
in which ISCU2 contains multiple conformation states is consistent with results on E. 
coli IscU from the Markley lab (see above). The nature of the conformational change in 
human ISCU2 is not known, but may be related to the helix-to-coil transition proposed 
to position C104 for sulfur transfer from NFS1 (Figure 1-11).67 This model is especially 
attractive due to the close proximity of M106 to the chaperone binding motif, LPPVK 
(residues 97-101), and C104.  
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Figure 1-11. A model is hypothesized for the FXN-based selection of the active ISCU2 
conformation. ISCU2 exists in two conformations with the helical, inactive, 
conformation being preferred. FXN binding interacts with and stabilizes the ISCU2 coil 
conformation that positions C104 to accept sulfur from NFS1.69 
 
 
 
There is currently limited structural information for human FXN binding to the 
SDUF complex or the E.coli homolog CyaY to the IscS-IscU complex.  Mutational and 
pull-down studies reveal that IscS substitutions R116E, R220E, R223E, R225E/E227R, 
G234L, R237E/M238E, A327V, and R340E diminish interactions with CyaY and 
provide a potential binding site (Chapter II).31 Additionally, NMR studies indicate 
residues along the acidic patch on CyaY (residues D22, D23, S28, D29, E33, F43, and 
E44) were perturbed upon the addition of IscS indicating a potential binding 
interaction.70 Mutation studies on human frataxin have also indicated that residues on the 
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acidic patch (E108, E111, D124) and also residue W155 are important for the 
interactions with the human cysteine desulfurase and scaffold proteins (Figure 1-12).64 
 
 
 
Figure 1-12. Frataxin mutated residues that diminish or lose binding affinity to NFS1 
and ISCU2 are highlighted as yellow sticks on the wild-type structure (PDB 3S4M). 
 
 
 
After cluster assembly, additional machinery is required to transfer the cluster 
from the SDUF complex to apo target proteins. In humans, the equivalent of the E. coli 
HscA chaperone is HSP70, which is also known as GRP75 and mortalin, whereas the 
equivalent to HscB is known as HSC20, also known as DNA J type-III co chaperone.71  
The interactions of HSP70 and HSC20 have been less well studied in the human system.  
The interactions determined by yeast two-hybrid and pull down studies indicate that 
Hsc20 interacts with ISCU2 and HSP7071 and co-immunoprecipitation experiments 
indicate an interaction between FXN and GRP75.72 There remains much to be learned 
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about the chaperone-facilitated transfer of Fe-S clusters from the SDUF complex to apo 
targets such as ferredoxin.24 
 
CONNECTION BETWEEN Fe-S CLUSTER BIOSYNTHESIS AND HUMAN 
DISEASE 
Mutations in the Fe-S assembly pathway in humans can manifest itself in a 
number of diseases (Figure 1-13).11 The most commonly inherited ataxia, Friedreich’s 
ataxia (FRDA), is an autosomal recessive neurodegenerative disease associated with 
deficiencies in the protein frataxin.63 The most common mutation is a GAA repeat on the 
first intron of the gene.63  In healthy individuals, the occurrence of this insert is between 
6 to 36 but in diseased patients, the number of repeats is greatly increased to 70-1700 
causing a phenotypic progressive gait and limb ataxia, muscular weakness in the legs, 
and dysarthria.63  Most FRDA patients have GAA repeats on both alleles. A small subset 
of FRDA patients exhibits a GAA repeat on one allele and a missense (point mutant) on 
the other allele. Both classes of FRDA patients exhibit decreased amounts of functional 
frataxin that manifests as a decrease in iron sulfur cluster assembly.73 
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Figure 1-13 This model highlights the various diseases associated with deficiencies in 
Fe-S assembly. Reprinted with permission from Trends in Endocrinology and 
Metabolism, 21:302-314.Copyright 2010 Cell Press.11 
 
 
 
The ability of these FXN mutants to bind its partner proteins through pull down 
assays,72, 74 stimulate the cysteine desulfurase activity and Fe-S cluster assembly 
activities, and bind the SDU complex has been studied.66, 75 The results of these studies 
indicate that there is a general correlation between the ability of the FXN mutants to bind 
the SDU complex and stimulate the cysteine desulfurase activity.75 Mutations such as 
W155R that are highly compromised in both binding and activation of the SDU complex 
tend to have early onset disease progression, whereas mutants such as R165C and 
N146K that have a more modest loss of binding and/or activation tend to have an 
unusually mild disease progression.75 
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 Frataxin has had many proposed roles from iron trafficking and storage to acting 
as an allosteric switch to regulate Fe-S biosynthesis (Figure 1-14).76, 77  It has recently 
been discovered that the role of frataxin in the Fe-S assembly pathway differs between 
bacteria and humans.78  In E. coli, the addition of the frataxin homolog, CyaY, decreases 
the Fe-S cluster assembly activity,70, 78 whereas in humans, the addition of FXN 
stimulates the Fe-S cluster activity.33, 78 
 
 
 
Figure 1-14. Various proposed roles of frataxin are shown from iron storage and 
chaperone roles to frataxin acting as a metabolic switch. Reprinted with permission from 
PNAS, 107:10775-10782. Copyright 2010.76 
 
 
 
Additionally, a mutation on ISCU2 has recently been identified as the source of 
the disease Myopathy with exercise intolerance.79, 80  This disease is an inherited 
autosomal recessive disease specific to northern Sweden, which has a phenotype of early 
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on-set fatigue, dyspnoea, and palpitations upon light exercise.79  ISCU2 myopathy is 
caused by a homozygous point mutation on intron 4 that causes the intron to have a 
100bp fragment insertion between exons 4 and 5 and also includes a premature stop 
codon in the open reading frame of the mRNA of ISCU2.81 A more severe progression 
of the disease is caused by a heterozygous mutation to one allele in which a missense 
mutation in exon 3 is reported.79, 81  The transcribed ISCU2 has a point mutation at a 
conserved glycine to glutamate.  It is unclear how this mutation alters the functional 
properties of ISCU2. 
 
CONCLUSION  
Despite the information on the prokaryotic IscS-IscU complex, many questions 
remain in both prokaryotic and also eukaryotic Fe-S cluster biosynthesis. For example, 
there exists no structural information for the cysteine desulfurase, NFS1, its co-protein 
ISD11, or the scaffold, ISCU2. The interaction between NFS1 and ISD11 and the role 
that ISD11 plays in Fe-S cluster assembly are not known. Additionally, the surfaces of 
interaction for the regulator of activity of the human Fe-S cluster assembly complex, 
frataxin, is not well defined with either NFS1 or ISCU2 in terms of the protein complex. 
Therefore, one goal of this dissertation was to use hydroxyl radical footprinting to define 
the protein interfaces for the SDUF complex (Chapter II). This protein interface data 
provides an initial testable model for the complexes than can be evaluated through 
mutagenesis experiments and also coupled to other ongoing low-resolution approaches 
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in the Barondeau lab such as SAXS and electron microscopy to generate a more 
sophisticated model of the SDUF complex.  
Very little is known about the Fe-S cluster transfer reaction in humans. Once the 
SDUF complex has assembled a Fe-S cluster it is unclear at what stage and oligomeric 
state ISCU2 interacts with the chaperones to deliver the Fe-S cluster to apo targets. 
Possible models include larger macromolecular complexes with interactions between 
SDU and SDUF Fe-S assembly complex and the molecular chaperones (Figure 1-15, top 
paths) and models in which ISCU2 dissociates from the SDUF complex before 
delivering the cluster to the target protein (Figure 1-15, bottom paths). In the dissociation 
models, the loss of ISCU2 from the SDUF complex could be induced by chaperone 
binding or occur spontaneously. In addition, the released ISCU2 could interact with the 
chaperones as a monomer or dimer. To understand the molecular choreography of these 
events, a strategy has been initiated in which an individual component, namely FXN, 
was labeled with a fluorophore. Labeling the component with fluorophore is a powerful 
approach that can allow the determination of protein binding constants, size information 
(fluorescence anisotropy experiments) and distance measurements (Förster resonance 
energy transfer, FRET, between appropriately labeled proteins). In Chapter III, 
fluorescence anisotropy experiments were initiated on labeled FXN and a FXN variant 
to help distinguish Fe-S transfer models. 
ISCU2 variants were then designed to test aspects of the pre-equilibrium model 
in which ISCU2 exists as a mixture of function and non-functional states.67 Recent 
experiments reveal E. coli IscU exists as a mixture of ordered and dynamically 
 24 
 
disordered states, that the D39A (E. coli numbering) variant favors the ordered state, 
possibly by removing buried charge, and that this variant appears to enhance Fe-S 
cluster binding and complex formation with IscS.35 Moreover, additional experiments 
suggest a model in which FXN favors an ISCU2 helix-to-coil transition, which may be a 
component of this conformational change, to activate the human Fe-S assembly system.  
In Chapter IV, variants of ISCU2 at position K101, which is hypothesized to be a 
component of the helix-to-coil transition and interact with FXN, were coupled to 
previously made ISCU2 and FXN variants to evaluate FXN binding and activation of the 
cysteine desulfurase and Fe-S assembly activities. 
In addition to the structural studies of the SDUF complex, more specific 
experiments were designed to understand the impact of clinical (G16E) ISCU2 mutants 
on Fe-S cluster biosynthesis (Chapter V).   
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Previous experiments correlated defects in FXN missense mutations in binding and 
activation of the SDU complex with the severity of disease progression.75 In Chapter V, 
similar experiments on the G16E ISCU2 missense mutant are described that reveal a 
significant loss in binding affinity of the clinical mutant to the Fe-S cluster assembly 
complex.  Once the weaker binding is taken into account, this clinical mutant has 
cysteine desulfurase and Fe-S cluster assembly activities similar to wild-type ISCU2 and 
highlights the importance of a high affinity assembly complex for synthesizing Fe-S 
clusters. 
Additionally in Chapter V, the human D37A and L107Q ISCU2 variants were 
designed to stabilize the structured state and test their ability to bind the SD complex and 
interact with FXN. The functional properties of the variant SDUF complexes were also 
evaluated with cysteine desulfurase and Fe-S cluster assembly experiments.  
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Figure 1-15. A model of Fe-S cluster transfer from the SDUF complex to apo target 
proteins.   The NFS1/ISD11 (SD) is shown as a yellow sphere, ISCU2 monomer is 
shown as a blue crescent and FXN is shown in red.  The chaperones HSP70 (pink) and 
HSC20 (purple) are shown as a complex that can interact with the Fe-S cluster 
biosynthesis complexes or its components to transfer the [2Fe-2S] cluster to apo target 
proteins. 
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CHAPTER II 
PROTEIN-PROTEIN INTERACTIONS OF THE SDUF COMPLEX DETERMINED 
BY HYDROXYL RADICAL FOOTPRINTING 
 
INTRODUCTION 
 Iron-sulfur (Fe-S) clusters are integral cofactors found in every life form from 
prokaryotes to eukaryotes, and are involved in critical cellular processes such as nitrogen 
fixation, respiration, DNA repair and sensing of reactive oxygen and nitrogen species.1  
In bacteria, Fe-S clusters are assembled through one of three pathways, namely the 
nitrogen fixation pathway (NIF), sulfur mobilization pathway (SUF), and the iron sulfur 
cluster formation pathway (ISC).82 Homologues of many of the components from the 
prokaryotic system are conserved in eukaryotes.22 Specifically, the primary pathway for 
Fe-S cluster assembly in humans is the ISC system located in the mitochondria. This Fe-
S assembly system contains a cysteine desulfurase, NFS1, which, along with its co-
protein ISD11, is responsible for the conversion of cysteine to alanine. During catalysis a 
persulfide is generated on a mobile loop cysteine on NFS1 and the terminal sulfur is then 
transferred to the scaffold protein ISCU2 for Fe-S assembly.37, 83, 84These three 
components, NFS1/ISD11 and ISCU2, form a low activity Fe-S assembly complex 
named SDU that can be activated by the binding of frataxin (FXN).33The active four 
protein component SDUF complex was first identified by native gel electrophoreses and 
has a molecular mass of approximately 190 kDa as determined by gel filtration 
chromatography and intact mass spectrometry, which suggests an approximate 
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stoichiometry of 1:1-2:1:1 for the NFS1/ISD11/ISCU2/FXN components, respectively.33, 
64 
In recent years, the ISC Fe-S cluster assembly system has been studied 
extensively in vivo and in vitro from a variety of organisms to gain a mechanistic 
understanding of this pathway and determine the effect of deficiencies in assembly 
components at the cellular or organism level.77 In contrast, the structural features of 
many of the Fe-S assembly components and molecular details for Fe-S assembly 
complexes in eukaryotes are currently lacking. Elucidating the structures of the 
individual proteins and details of the protein-protein interactions of the associated 
protein complexes will aid in constructing testable models that will provide a deeper 
understanding and context for mechanistic studies. Moreover, such studies may also 
provide a basis to understand interactions between the core SDUF Fe-S cluster assembly 
complex and additional assembly, chaperone, and accessory proteins that assist in Fe-S 
cluster biosynthesis.52, 85 
The largest subunit of the ISC Fe-S assembly complex is the cysteine 
desulfurase, which is named NFS1 in eukaryotes and IscS in prokaryotes. Crystal 
structures of the E. coli IscS (PDB 1P3W)30 as well as the homolog from the NIF 
system, NifS, from Thermotoga maritima (PDB 1EG5)86 reveal an overall dimeric 
structure, with active site PLP cofactor of each active site located more than 17 Å from 
the catalytic cysteine, Cys328(E. coli numbering).30 This catalytic cysteine is on a 
mobile loop that is often disordered in crystal structures and is consistent with the 
required large-scale structural rearrangement required to transfer the sulfur from the PLP 
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at the active site to various acceptor proteins.30, 31  In contrast, there is no known 
structure of a cysteine desulfurase from an eukaryotic system.  The human NFS1 shares 
an approximate 51% sequence identity with E. coli IscS, exists as a ~90 kDa dimer 
based on gel filtration chromatography experiments77 and have further been 
characterized by pull-down, biochemical and mutational studies to determine binding 
interactions with IscU and frataxin,31 and NMR studies show complex formation 
between IscS and IscU.34 Additionally, the co-protein ISD11 localizes to the 
mitochondria and is required for the stability and activity of NFS1 in eukaryotic 
organisms in vivo,61, 87 and for the generation of functional recombinant NFS1 in 
bacteria.77 Although experimental data for the 10.6 kDa ISD11 protein is lacking, 
secondary structure and de novo structure prediction support a 3-helix bundle protein 
fold.88The number, oligomeric state, and position of ISD11 molecules on the surface of 
NFS1 are not known. 
The scaffold protein, which is named ISCU2 for humans andIscU in prokaryotes, 
is the second component of the ISC Fe-S assembly complex and has been primarily 
studied by NMR spectroscopy and X-ray crystallography in bacteria.  Solution structures 
have been solved of homologous proteins from E. coli of wild-type and D39A (E. coli 
numbering), a mutant which is known to bind a Fe-S cluster tighter,36, 40 a Zn2+ bound 
IscU from Haemophilus influenza (PDB 1R9P),36 and also an unpublished structure from 
Mus musculus (PDB 1WFZ). These NMR and additional CD spectroscopy studies reveal 
that wild-type apo-IscU is purified as a monomeric protein with an αβ fold and high α-
helix content,89 a flexible N- and C-terminus, and exists in two freely interconverting 
 30 
 
states in solution.35, 40  Markley et al determined that wild-type apo-IscU exists 
approximately 70% in the structured and 30% in the disordered form but the equilibrium 
can be shifted by incorporating single amino acid point mutations, such as the D39A 
substitution, which shifts the equilibrium to ~95% structured.35, 40  Markley et al further 
show that it is the disordered state of IscU that preferentially interacts with IscS.35 
Protein crystallization has been successful from a homolog from E. coli with a zinc 
bound to the three active site cysteine residues (PDB 1SU0)90 and also from Aquifex 
aeolicus which was crystallized with a single [2Fe-2S] cluster between a trimer of IscU 
molecules (PDB 2X7E).91 
Recently, groundbreaking crystallographic studies by two separate groups 
revealed the protein-protein interactions for the IscS-IscU complex from prokaryotes.31, 
32 The Cygler group published a crystal structure of the E. coli complex (PDB 3LVL)31 
that revealed the N-terminus of the scaffold protein IscU changes from a flexible coil to 
a short α-helix upon forming a complex with IscS. This conclusion is consistent with 
pull-down results that indicate the N-terminally truncated IscU loses binding affinity 
toIscS.31 Additionally, the Fontecilla-Camps and Dean groups determined a 2.5 Å co-
crystal structure of IscS-IscU from A. fulgidus that contained a bound 2Fe-2S cluster to 
one subunit (PDB 4EB5).32 The protein-protein interactions of the scaffold and cysteine 
desulfurase from E. coli and A. fulgidus are very similar indicating that these interactions 
might be conserved across organisms.31, 32 
The fourth component of the Fe-S cluster assembly complex is frataxin which 
has recently been identified as an allosteric activator for the SDU complex.64, 77 In 
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contrast to the activator role for the human system, addition of the E. coli homolog CyaY 
to the IscS-IscU complex appears to inhibit Fe-S cluster assembly.78, 92 Human FXN is 
the only component of the SDUF complex in which protein crystallography information 
is available.75, 93, 94The structures of FXN homologs from yeast (Yfh1)95, 96 and E. coli 
(CyaY)94, 97, 98 have also been determined and are very similar to human FXN. The 
overall sequence identity is relatively low between E. coli CyaY and yeast Yfh1 or 
human FXN at 26.4% and 24.5%, respectively, but share an overall compact αβ 
sandwich fold consisting of a 6 antiparallel β-sheets panel flanked on either side by 2 
helices, α1 and α2 (Figure 2-1).99, 100 The conserved residues between CyaY, Yfh1, and 
FXN are shown in blue on the orange CyaY molecule (PDB 1WE4) and the red FXN 
molecule (PDB 3S4M). Mutation of conserved residues on β3 and β4such as V144, 
N146, Q148, Q153, W155, and R165 (human numbering), diminish the ability of CyaY 
to pull down IscS,64 decrease the ability of FXN to stimulate the cysteine desulfurase, 
Fe-S cluster biosynthesis activities, and FXN binding to the SDU complex67, 75 revealing 
the importance of these residues in the Fe-S cluster assembly complex.  There currently 
exists no model of the four-protein SDUF complex from eukaryotes.  
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Figure 2-1.Structural overlay and conserved residues of human and E. coli frataxin 
homologs. Ribbon diagrams for E. coli CyaY (orange, PDB 1EW4) and human FXN 
(red, 3S4M) crystal structures reveal similar tertiary structures and a clustering of 
conserved residues (blue). 
 
 
 
Many standard structural characterization techniques have been unsuccessful or 
are inappropriate for the proteins and complexes responsible for Fe-S assembly in 
humans. Specifically, protein crystallography has been unsuccessful for human NFS1, 
ISD11, and ISCU2 and the SD, SDU, and SDUF complexes. NMR requires very high 
protein concentrations, labeling of subunits in isotope rich media or buffers, and the size 
of the complexes pushes or exceeds the limitations of the technique.  Techniques such as 
hydrogen deuterium exchange (HDX) mass spectrometry (MS) have gained popularity 
in determining protein dynamics,101-104 protein-ligand,105, 106 and protein-protein 
interactions107 but this technique has limitations in that the label is labile and will readily 
exchange with protons in the buffer solution, known as back exchange. Additionally, the 
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conditions required to quench the exchange reaction make necessary the use of acid 
proteases, which do not cleave after specific amino acid residues making the data 
analysis complex. Recently, hydroxyl radical footprinting by synchrotron radiation 
monitored by mass spectrometry has been used to understand the multimerization 
reactions of insulin,108 the interactions between myosin and actin,109 or the conformation 
dynamics between protein and receptor or ligand complexes.110, 111  Hydroxyl radical 
footprinting is an attractive alternative to other structure characterization techniques 
because it requires significantly lower protein concentration (~10 µM), the reaction 
times are short (<30 ms) and the modifications are covalent allowing for protein 
digestion with specific proteases such as trypsin. Additionally, generating the hydroxyl 
radicals by synchrotron radiation does not require the addition of radical forming 
species, such as hydrogen peroxide.  The modifications are monitored by MS which also 
requires very little sample, has fast experiment time, and high sensitivity to low 
abundance species.   
For these reasons, hydroxyl radical footprinting by synchrotron radiation 
monitored by matrix-assisted laser desorption ionization (MALDI) time of flight (TOF) 
mass spectrometry was used to probe the interactions of humanISCU2 withNFS1-ISD11 
(SD) to form the NFS1/ISD11/ISCU2 (SDU) complex. Further, the addition of FXN to 
the SDU complex to form the NFS1-ISD11-ISCU2-FXN (SDUF) was monitored to 
better understand the interactions that are critical for complex formation and activation. 
Models for these complexes were generated and then evaluated using criteria such as 
electrostatic potentials and previous mutational studies.  These structural models lead 
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directly to the generation of specific hypotheses that will be partially tested in later 
chapters of this dissertation and also with future studies in the Barondeau lab. 
 
EXPERIMENTAL PROCEDURES 
                                                      Human FXN, ISCU2, 
and SD were recombinantly purified as previously described75 and were buffer 
exchanged into 1X PBS (10 mM Na2HPO4, 2 mM KH2PO4 pH 7.4, 137 mM NaCl, 2.7 
mM KCl) using Micro Bio-Spin P-6 buffer exchange columns (Bio-Rad Laboratories), 
which had previously been conditioned with 1X PBS.  To assemble the SDU or SDUF 
complex, SD was incubated with 5 equivalentsISCU2 (SDU) or 5 equivalents each 
ISCU2 and FXN (SDUF) on ice for 30 minutes.  Excess ISCU2  (14 kDa) and/or FXN 
(14 kDa) were removed by applying the complex to a 30 kDa MW cutoff Vivaspin 500 
(GE Life Sciences) concentrator and centrifuging for 5 minutes at 4 oC at 8000 x g. The 
protein complex that did not flow through the concentrator was buffer exchanged into 
1X PBS as above.  The protein samples at a final concentration of 10 μM in 1X PBS 
buffer were frozen in liquid nitrogen and were shipped overnight to Brookhaven 
National Lab (BNL) on dry ice. Sample concentrations were determined using the 
extinction coefficient at 280nm (ISCU2, ε280 = 8250 M
-1cm-1 and FXN ε280 = 26,030 M
-
1cm-1) and 420nm (SD, SDU, SDUF; ε420 = 10.9 mM
-1cm-1). Upon arrival to BNL, the 
samples were stored at -20 oC until X-ray exposure. 
Sample Exposure.  Synchrotron dose response was determined for each sample 
as previously described.112 Briefly, a fluorescent molecule such as an Alexa fluorophore 
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was added to a small quantity of each protein or complex sample and exposed to 
synchrotron radiation.  The fluorophore was quenched by the excess radicals not 
absorbed by the protein molecule or complex and rate of quenching was used to 
determine the amount of exposure required to label each sample. The exposure time 
determined using this method was then used to modify each sample or complex prior to 
quenching the reaction with 10 mM methionine amide to prevent further oxidation.112 
Specifics of the configuration of beamline X28C and sample exposure followed 
previously described protocols.112 Three independent data sets for each sample were 
collected for analysis. Differences in beam flux and currents (approximate 10% 
decrease) could account for the modest differences in the rates of modification for the 
individual experiments. 
Preparation and MALDI TOF Analysis of Irradiated Samples. After exposure to 
hydroxyl radicals and quenching, the samples were shipped from BNL on dry ice, 
thawed upon arrival, and digested with trypsin.  For the ISCU2 and FXN samples, 
trypsin was added at a 1:50 dilution; for SD, SDU, and SDUF, trypsin was added at a 
1:25 dilution to ensure efficient digestion of the complexes.  The protein digests were 
incubated at 37 oC for 3.5 hours before the tryptic peptides were acidified to a final 
concentration of 0.1% trifluoroacetic acid (~pH 2-3).  Approximately 60-70 μl of the 
sample was desalted using a C18 Zip-Tip® pipet tip (Millipore), eluted in 4 µl, mixed 1:1 
with MALDI matrix (5 mg/ml α-cyano-4-hydroxycinnamic acid, 50% (v/v) acetonitrile, 
10 mM ammonium dihydrogen phosphate, 0.1% trifluoroacetic acid), and 1 µl of the 
resulting mixture was spotted onto a MALDI sample plate in duplicate.  Dr. Pei-Jing 
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(Peggy) Pai in the Dr. David Russell Biological Mass Spectrometry Laboratory 
performed the MALDI TOF MS and MS/MS experiments using a 4800 TOF/TOF 
Analyzer (Applied Biosystems, Framingham, MA).  Collision-induced dissociation 
(CID) spectra were acquired using 2 eV of collision energy of the 30 most abundant 
peptides in each spectrum.   
Theoretical masses and mass to charge ratios (m/z) were calculated from the known 
peptide sequence and used to identify the unmodified peptides for the different proteins 
and complexes. Peptides that were unable to be confidently assigned by the calculated 
m/z were confirmed by MS/MS if the data was collected. Modified peptides were 
identified by sequence-specific changes in mass compared to the unmodified peptide 
with 100ppm allowed error. Most often this change in peptide molecular weight was +16 
Da mass increments due to oxygen incorporation. The fraction unmodified was 
calculated113, 114 for each peptide of ISCU2, FXN and for the peptides in the SD, SDU, 
and SDUF complex by dividing the peak height of the monoisotopic peak for the 
unmodified peptide by the sum of the peak heights of the monoisotopic peaks for the 
unmodified and modified peaks (Equation 2-1). 
  
                       
            
(                         )
   (2-1) 
 
The fraction unmodified was plotted as a function of exposure time and the 
graphs were fit to a first order process in KaleidaGraph software using Equation 2-2. The 
variable y represents the fraction unmodified at a given exposure time (t) and k is the rate 
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constant in s-1.112, 114, 115  The reported error for each rate value is an error in the fit of the 
data.   
 
               (2-2) 
 
Homology Models for Human NFS1 and ISCU2. Homology models were 
generated for of human NFS1 and ISCU2 using SWISS-MODEL 
(http://swissmodel.expasy.org/).116-118Briefly, the model was based on the IscS and IscU 
coordinates from the E. coli IscS-IscU complex (PDB 3LVL)31 and the sequence of 
human NFS1 and ISCU2.  In addition, a model of the complex between NFS1 and 
ISCU2 was generated based on the same IscS-IscU co-crystal structure.   
Ab initio Structural Model for Human ISD11. ISD11 has been predicted to have a 
high helical propensity88 but there is no known solution or crystal structure of human 
ISD11 or a ISD11 homolog organism. Therefore, a structural model was generated using 
the Robetta Full-Chain Protein Structure Prediction Server http://robetta.bakerlab.org/. 
The predicted 3-helix bundle is consistent with a published structural model.61 
Calculation of Electrostatic Potential for SDUF Components. The electrostatic 
surface potentials for the individual components of the human Fe-S cluster assembly 
complex were determined using CHARMM-GUI PBEQ Solver with the default input 
settings (http://www.charmm-gui.org/?doc=input/pbeqsolver).  The generated coordinate 
files for human NFS1, ISD11, and ISCU2 models and the human FXN crystal structure 
(PDB 3S4M) were individually uploaded onto the CHARMM server and the 
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electrostatic potentials and solvation energies for each structure were generated.  The 
electrostatic maps were displayed at the solvent accessible surface using PyMOL 
software (PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC.).  The 
electrostatic scale is from -1.0 to 1.0 kcal/(mol · unit charge). The regions with negative 
electrostatic potential are shaded red, whereas regions with positive electrostatic 
potential are shaded blue.   
 
RESULTS 
 Here our objectives were (1) to identify the protein interaction interfaces for the 
cysteine desulfurase and scaffold proteins from the human Fe-S assembly complex, (2) 
to identify the binding interfaces between FXN and the proteins of the SDU complex, 
and (3) compare the interactions uncovered in these studies to what is already known 
from homologous proteins from the E. coli co-crystal structure. To fulfill these 
objectives, samples of individual proteins or complexes were exposed to synchrotron 
radiation for variable amounts of time to become labeled with hydroxyl radicals, 
quenched by the addition of 10 mM methionine, digested with trypsin, and the resulting 
peptides were subjected to analysis by MALDI TOF mass spectrometry (see Methods).   
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To ensure reproducibility, the only peptides included in the final analysis were 
those identified by their m/z in at least two of the three independent data sets.  We 
classified peptides as becoming modified if their m/z value shifted by the amount 
corresponding to the addition of oxygen atoms (+16 Da, +32 Da, +48 Da, etc.) upon 
exposure to hydroxyl radicals.  The peptides from each protein were identified from 
individual and complex analysis and were compared over the course of the three separate 
experiments.  For the ISCU2 protein, eight unique peptides were identified in the 
hydroxyl radical footprinting experiments, corresponding to ~55% sequence coverage 
(Figure 2-2).  The peptides identified are shown as bars over the protein sequence 
(Figure 2-2A) and are mapped onto the human model of ISCU2 protein (Figure 2-2B) 
with the identified peptides shown in blue with the regions unobserved in gray and the 
active site cysteines highlighted by sticks..  These peptides were observed in the 
individual ISCU2 experiments as well as in the SDU and SDUF complexes.  The 
changes in rates of modification of these peptides were used to determine regions of 
interaction to NFS1 (SDU complex) and FXN (SDUF complex). 
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Figure 2-2. ISCU2 was digested with trypsin and the fragments observed from 3 separate 
hydroxyl radical experiments are shown (A) over the protein sequence by blue bars or 
(B) displayed by blue peptides on the model of human ISCU2 with the active site 
cysteine residues shown in yellow. Eight unique peptides were identified covering 
approximately 55% of the protein sequence. 
 
 
 
 
 
A. 
B. 
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Similarly, the peptides from NFS1 were identified after trypsin digestion of the 
SD, SDU or SDUF complexes. The rates of modification for the 7 peptides identified 
(~27 % sequence coverage) were monitored to determine the sites of interaction for 
ISCU2 in the SDU complex and FXN on the SDUF complex. The sites of interaction for 
ISD11 could not be determined because NFS1 could not be purified without ISD11. The 
peptides identified in at least 2 of the three experiments are displayed above the protein 
sequence by the blue bars (Figure 2-3A) and on the model of human NFS1 dimer 
generated using the human sequence and the coordinates from the E. coli IscS crystal 
structure (see Methods) by highlighting the peptides in blue (Figure 2-3B). The peptides 
were mapped onto both subunits of the NFS1 dimer with the unmodified or unidentified 
peptides displayed in gray.  The protein sequence contains the N-terminal histidine tag 
used for protein purification (the N-terminal ~20 amino acids).  The residue numbers are 
shown at the left of each line. 
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Figure 2-3. Peptides identified from the SD, SDU, and SDUF complexes after trypsin 
digestion of NFS1 in the 3 independent hydroxyl radical footprinting experiments are 
shown (A) above the protein sequence by blue bars or (B) mapped onto the model of 
human NFS1 dimer shown in blue.  Seven unique peptides were identified 
corresponding to approximately 27% sequence coverage. 
 
 
A. 
B. 
 43 
 
Finally, the peptides from FXN identified either from FXN or from FXN in the 
SDUF complex are shown over the protein sequence (Figure 2-4A) in red or on the 
crystal structure of human FXN (PDB 3SS4M) by red peptides (Figure 2-4B). The 
regions not observed in the hydroxyl radical footprinting experiments are shown in gray 
on the structure. Seven unique peptides were identified covering approximately 48% of 
the FXN sequence.  
 
 
 
Figure 2-4.  The peptides of FXN that were identified by trypsin digests after hydroxyl 
radical modification for at least two of the three independent experiments are shown (A) 
over the protein sequence by red bars or (B) as red peptides on the structure of human 
FXN (PDB 3S4M). Seven unique peptides were identified correlating to approximately 
48% sequence coverage. 
A. 
B. 
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Changes in Peptide Modification upon the Formation of the SDU Complex. The 
peptides from ISCU2 and NFS1 mentioned were monitored in the SDU complex as well 
as in for the individual proteins.  The changes in rates of modification upon complex 
formation indicate the regions involved in protein-protein interactions or protein 
conformational change protecting the region(s) from solvent exposure to hydroxyl 
radicals.  First, the MALDI TOF mass spectra from ISCU2 either alone or in the SDU 
complex were analyzed to determine the changes rates of modification for the peptides 
on ISCU2 (Appendix Figures A1-A52). The relative amount of modification was 
determined by observing oxidation events for the peptide, where one oxidation event 
was defined as the appearance of a peak at +16 Da m/z spacing from the parent, 
unmodified peak and two oxidation events were determined by the observation of a peak 
at [M+H+32]+ Da with the trend continuing in +16 Da increments. The fraction or 
percent of the peptide that was unmodified was calculated using Equation 2-1 then 
plotted as a function of exposure time and the resulting data was fit to Equation 2-2 in 
KaleidaGraph (Figure 2-5).  The calculated rates of modification for each peptide from 
ISCU2 or the SDU complex are shown in Table 2-1.  The error associated with each 
calculated rate reflects the error in the fit.  Additionally, the cases in which the amount 
of modification appears to decrease at longer time points is likely due to low signal 
intensity of the parent and modified peaks.  This led to potentially not observing 
modified species or relative abundance values that were not reflective of the true amount 
of modification.  The data revealed one peptide on ISCU2 that showed a decrease in 
modification upon binding the SD complex, specifically residues 5-13 (unmodified m/z 
 45 
 
1128.5).  This peptide underwent 3 oxidation events noted by the appearance of peaks at 
1144.5, 1160.5, and 1176.6 m/z in ISCU2 and the SDU complex with the relative 
abundance of the oxidized peaks being lower in the SDU complex.  Furthermore, two 
ISCU2 peptides (residues 56-76, unmodified m/z 2190.1 and residues 102-113, 
unmodified m/z 1330.7) were identified in two independent experiments and showed 
protection in one of those experiments (Figure 2-5, Table 2-1).  In experiment 3, the 
ISCU2 peptide 56-76 at m/z 2190.1 had peaks appear at 2206.1, 2222.1, 2238.1, and 
2254.0 m/z (4 oxidation events) as a function of exposure to hydroxyl radicals but in the 
SDU complex, only peaks at 2206.1 and 2222.1 m/z (2 oxidation events) were observed.  
Additionally in experiment 3, the ISCU2 peptide 102-113 at m/z 1330.7 had peaks 
appear at 1314.6, 1346.6, and 1362.6 m/z upon exposure to hydroxyl radicals.  When 
ISUC2 bound the SD complex to form the SDU complex, this peptide only had a peak at 
m/z 1346.6 appear indicating protection of this peptide in the SDU complex.  The 
appearance of the peak at m/z 1314.6 in the sample for ISCU2 corresponding to residues 
102-113 relates to a loss of 16 Da, which is one potential modification for cysteine 
containing peptides.   
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Interestingly, one peptide on ISCU2 (residues 58-76, m/z 1914.8), appeared 
much more susceptible to oxidation (Table 2-1) upon SDU complex formation for two 
independent experiments while the peptide was not observed in the third experiment.  In 
experiment 2, for both ISCU2 and ISCU2 in the SDU complex, peaks at 1930.8, 1946.8, 
and 1962.9 m/z (3 oxidation events) appeared upon exposure to hydroxyl radicals but the 
modified peaks in the SDU complex were more abundant compared to the unmodified 
peak than for ISCU2 alone.  In experiment 3 for the same peptide, only peaks at 1930.9 
and 1946.9 m/z became more abundant with ISCU2 formed the complex with SD. 
ISCU2 peptides for other regions of the protein (residues 14-20, 41-48, 77-87, and 114-
120 corresponding to 732.4, 972.5, 1188.6, and 751.4 m/z, respectively) did not show a 
change in modification in any of the three independent experiments (Figure 2-5, Table 2-
1).  The regions on ISCU2 that underwent protection or additional modification upon 
complex formation with NFS1 have been mapped onto the model of human ISCU2 with 
the protected peptide shown in blue, the more modified peptide (residues 58-76) shown 
in orange, and the active site cysteines highlighted in yellow (Figure 2-6).  
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Figure 2-5. The rates of modification are shown for the ISCU2 peptides generated from 
tryptic digests from: ISCU2 (dark gray) or ISCU2 from SDU (green).  The data from 
experiment 1 (solid lines), experiment 2 (dashed lines), and experiment 3 (dotted lines) 
are shown. 
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Figure 2-5. Continued. 
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Table 2-1. The rates of modification for peptides on ISCU2 that were observed in the 
ISCU2 and SDU samples. 
 
 
 
 
Figure 2-6. The peptides that underwent protection (residues 5-13, blue) or became more 
modified (residues 58-76, orange) upon complex formation with NFS1 were mapped 
onto the model of human ISCU2. The regions that were not observed or that did not 
undergo modification are shown in gray.  The active site cysteine residues are shown as 
yellow sticks.  
 
  
Experiment 1 Experiment 2 Experiment 3   
peptide m/z 
ISCU2 
(sec-
1
) 
ISCU2 
from SDU 
(sec-
1
) 
ISCU2 
(sec-
1
) 
ISCU2 
from SDU 
(sec-
1
) 
ISCU2 
(sec-
1
) 
ISCU2 
from SDU 
(sec-
1
) 
Overall 
change from 
ISCU2 to SDU 
5-13 1128.5 15 ± 1 5 ± 3 25 ± 4 15 ± 5 9.7 ± 2 3.2 ± 0.6 decrease 
14-20 732.4 0 0 4 ± 4 0 0 0 none 
41-48 972.5 0 0 0 0 0 0 none 
58-76 1914.8 n.d n.d. 50 ± 10 166 ± 24 55 ± 9 103 ± 33 increase 
77-87 1188.6 0 0 0 0 0 0 none 
102-113 1330.7 n.d n.d 324 ± 68 261 ± 32 72 ± 3 35 ± 4 decrease 
114-120 751.4 0 0 3 ± 3 0 0 0 none 
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In a similar manner, the rates of modification for NFS1 in the SD and SDU 
complexes were compared.  The MALDI TOF mass spectra were analyzed to determine 
rates of modification for NFS1 (Appendix figures A52-A81) and the relative abundance 
of the parent and modified peaks were monitored to calculate the fraction unmodified by 
Equation 2-1. The fraction unmodified was plotted against exposure time to determine 
the rate of oxidation using Equation 2-2 in KaleidaGraph.  The rate graphs for the 7 
NFS1 peptides corresponding to ~27% sequence coverage are shown (Figure 2-7) with 
the calculated rates of modification shown in Table 2-2.  The error associated with the 
rate of modification reflects the error in the fit.  In the cases where the modification 
appears to decrease as the exposure time increases is likely due to low peptide 
abundance in the MS spectra and does not reflect a change in modification due to protein 
conformational change or changes in protein-protein interactions. Comparison of the 
data from SD and SDU revealed two NFS1 peptides (residues 262-290, unmodified m/z 
3085.6 and residues 402-419, unmodified m/z 2160.1) that were less susceptible to 
oxidation upon SDU complex formation (Table 2-2, Figure 2-8). Interestingly, there is 
significantly more protection to the 262-290 peptide (two independent experiments) than 
for the C-terminal peptide (residues 402-419) upon forming the SDU complex (Table 2-
2).  
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For residues 262-290 in experiments 1 and 3, a peak at m/z 3101.6 appeared 
corresponding to one oxidation event as SD or SDU was exposed to hydroxyl radicals 
compared to the parent peak at m/z 3085.6.  In the SDU complex, the peak at m/z 3101.6 
was less abundant, relatively, than for the SD complex indicating a protection from 
hydroxyl radicals or conformational change.  The C-terminal peptide (residues 402-416) 
with a parent peak at m/z 2160.1 underwent one or two oxidation events as observed by 
the appearance of peaks in experiment 1 at m/z 2176.1 and in experiment 3 at 2176.1 and 
2192.1 m/z upon exposure to hydroxyl radicals; the relative abundance of the modified 
peaks decreased in the SDU complex compared to the SD complex in both experiments.  
There were 5 additional peptides that were observed in at least 2 of the experiments that 
were unmodified in either the SD or SDU complexes (residues 75-88, 89-105, 233-240, 
245-258, 363-379 corresponding to 1481.8, 1807.9, 848.5, 1485.8, 1484.7 m/z, 
respectively) indicating no change in conformation or interaction with additional 
complex components (Table 2-2, Figure 2-7).  
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Figure 2-7. The peptides observed in the hydroxyl radical footprinting experiments from 
NFS1 in the SD and SDU complexes are shown as a function of exposure time to X-ray 
radiation. The data from three independent experiments are shown with the peptides of 
NFS1 from SD (orange) and SDU (green). 
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Figure 2-7. Continued. 
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Table 2-2. The rate of modification was calcualted for peptides from NFS1 from the SD 
and SDU compelexes.  The instances where “0” is shown indicates that no modification 
was observed. 
  Experiment 1 Experiment 3  
NFS1 
peptide 
m/z 
NFS1 from SD 
(sec
-1
) 
NFS1 from 
SDU 
(sec
-1
) 
NFS1 from SD 
(sec
-1
) 
NFS1 from 
SDU 
(sec
-1
) 
Overall Change 
from SD to SDU 
75-88 1481.8 0 0 0 0 none 
89-105 1807.9 1 ± 1 0 0 0 none 
233-240 848.5 1.1 ± 0.4 0 0 0 none 
245-258 1485.8 5.1 ± 0.3 0.9 ± 0.6 0 0 none 
262-290 3085.6 192 ± 40 29 ±10 12 ± 3 1.1 ± 0.1 decrease 
363-376 1484.7 0 0 0 0 none 
402-419 2160.1 65 ± 27 37 ± 9 33 ± 9 21 ± 3 decrease 
 
 
 
 
 
 
Figure 2-8. The peptides that were protected from modification from NFS1 upon ISCU2 
binding to form the SDU complex are shown in blue on the model of human NFS1 
dimer. The peptides, which were not observed or were unmodified, are shown in gray. 
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Changes in Modification for the SDU Complex upon FXN Binding. Currently, 
there is a lack of structural information for how FXN binds and activates the low activity 
Fe-S assembly complex SDU. A similar hydroxyl footprinting strategy outlined above 
was used to examine how FXN alters the kinetics of modification for ISCU2 and NFS1. 
MALDI TOF mass spectra were analyzed to generate the rate graphs for ISCU2 and 
NFS1 shown in Figure 2-8 (Appendix figures A1-A81). Evaluation of the data showed 
there was one peptide on ISCU2 that exhibited protection upon FXN binding the SDU 
complex, namely residues 102-113 at peak m/z 1330.7 (Figure 2-9, Table 2-3).  In both 
the SDU and SDUF complexes, the modified species at peaks 1346.7 and 1362.7 m/z 
corresponding to 2 oxidation events were observed (experiment 2) but the overall 
abundance of the oxidized peaks decreased in the SDUF complex. In the third 
experiment for the SDU complex, the single oxidation event peak at m/z 1346.7 was 
apparent but upon FXN binding the complex, the m/z 1346.7 peak disappeared 
indicating that this peptide was protected from modification the SDUF complex (Figure 
2-9). The peptide that became protected upon FXN binding the SDU complex has been 
shown on the model of human ISCU2 in cyan with the active site cysteines highlighted 
in yellow (Figure 2-11). Additional ISCU2 peptides (residues 5-13 and 56-76, 
corresponding to unmodified peaks at 1128.5 and 2190.0 m/z, respectively) described 
above had similar or slightly decreased modification rates upon FXN binding (Table 2-
3). Unfortunately, no additional peptides on NFS1 were identified with altered 
modification rates when comparing the SDU and SDUF complexes (Figure 2-10, Table 
2-4).  
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Figure 2-9.  The peptides of ISCU2 that were observed in the three experiments from the 
SDU (green) or SDUF (cyan) complexes as a function of exposure time to hydroxyl 
radicals.  
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Figure 2-9.  Continued 
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Figure 2-10.The fraction unmodified for the peptides from NFS1 that were observed in 
the SDU (green) and SDUF (cyan) complexes were plotted as a function of exposure 
time to hydroxyl radicals. 
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Figure 2-10. Continued 
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Table 2-3. The rates of modification for peptides from ISCU2 from the SDU and SDUF 
complexes fit to Equation 2-2 are shown. 
  Experiment 1 Experiment 2 Experiment 3 
Overall 
change in 
ISCU2 from 
SDU to SDUF 
peptide m/z ISCU2 
from 
SDU 
(sec-
1
) 
ISCU2 
from 
SDUF 
(sec-
1
) 
ISCU2 
from SDU 
(sec-
1
) 
ISCU2 
from 
SDUF 
(sec-
1
) 
ISCU2 
from SDU 
(sec-
1
) 
ISCU2 
from 
SDUF 
(sec-
1
) 
5-13 1128.5 5 ± 3 7.2 ± 0.9 14 ± 5 9 ± 1 3.2 ± 0.6 3.2 ± 0.7 inconclusive 
14-20 732.4 0 0 0 0 0 0 none 
41-48 972.5 0 0  0 0 0 0 none 
56-76 2190.0 8.4 ± 2.4 12.3 ± 2 35 ± 11 0 20.2 ± 1 13 ± 5 inconclusive 
77-87 1188.6 0 0 0 0 0 0 none 
102-113 1330.7 n.d. n.d. 261 ± 32 108 ± 20 35 ± 4 0 decrease 
114-120 751.4 0 0 0 0 0 0 none 
 
 
Table 2-4. The rates of modification for peptides from NFS1 from the SDU and SDUF 
compelexes are shown calculated from Figure 2-10 and fit to equation 2-2. 
  Experiment 1 Experiment 3 Overall 
Change from 
NFS1 from 
SDU to SDUF 
NFS1 
peptide 
m/z 
NFS1 from 
SDU 
(sec
-1
) 
NFS1 from 
SDUF 
(sec
-1
) 
NFS1 from 
SDU 
(sec
-1
) 
NFS1 from 
SDUF 
(sec
-1
) 
75-88 1481.8 0 0 0 0 none 
89-105 1807.9 0 0 0 0 none 
233-240 848.5 0 2.3 ± 0.8 0 0 none 
245-258 1485.8 0.9 ± 0.6 5 ± 2 0 0 none 
262-290 3085.6 29 ±10 31 ± 6 1.1 ± 0.1 n.d. none 
363-376 1484.7 0 0 0 0 none 
402-419 2160.1 37 ± 9 17 ± 4 21 ± 3 4 ± 2 decrease 
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Figure 2-11. The peptide on ISCU2 that showed a decrease in oxidation upon the 
addition of FXN to the SDU complex to form the SDUF complex is shown in cyan 
(residues 102-113).  The active site cysteines are highlighted as yellow sticks.  The 
peptides that did not have changed modification kinetics or that were unobserved are 
shown in gray. The molecule is in the same orientation as the molecule in Figure 2-6. 
 
 
Changes in Modification to FXN upon Binding to the SDU Complex. The changes in 
FXN peptide oxidation were also monitored between FXN and binding FXN to the SDU 
complex.  The change in FXN modification rates was particularly evident due to the 
presence of 3 tryptophan residues in the sequence, which are easily modified by 
hydroxyl radicals in this 130 amino acid protein.  Although 7 peptides (~48% of the 
sequence) were identified for FXN, the residues of the acidic patch were not observed.  
Each peptide (residues 81-97, 148-164, 148-165, 153-164, 153-165, 165-171, 165-192) 
had decreased oxidation kinetics in the SDUF complex compared to FXN alone (Figure 
2-12, Table 2-5). The error associated with the rate reflects the error in the fit of the data.   
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Figure 2-12.Peptides generated by trypsin digestion of FXN that were oxidized by 
hydroxyl radicals are shown for three independent experiments for FXN alone (red) or in 
the SDUF complex (cyan). Data was fit in KaleidaGraph to Equation 2-2. 
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Figure 2-12. Continued. 
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Table 2-5. The rates of modification are shown for peptides of FXN from FXN or the 
SDUF complex upon exposure to hydroxyl radicals. 
  
Experiment 1 Experiment 2  Experiment 3 Overall 
change 
from FXN to 
SDUF 
peptide m/z 
FXN  
(sec 
-1
) 
FXN from 
SDUF 
(sec 
-1
) 
FXN 
(sec 
-1
) 
FXN from 
SDUF 
(sec 
-1
) 
FXN 
(sec 
-1
) 
FXN from 
SDUF 
(sec 
-1
) 
81-97 1819.8 37.6 ± 3.2 9.7 ± 2 25 ± 3 -- 22.4 ± 2.4 -- decrease 
148-164 1855.0 102 ± 5.2 
15.29 ± 
2.0 
117.2 ± 
9.9 
41.1 ± 1.8 55.3 ± 7.1 4.2 ± 0.68 decrease 
148-165 2011.1 
166.2 ± 
14 
36.8 ± 6.3 161.1 ± 13 65.5 ± 7.6 116.1 ± 11 
11.1 ± 
0.32 
decrease 
153-164 1286.7 n.d. n.d.  80.3 ± 3.4 45.0 ± 4.3 52.6 ± 11.5 0 decrease 
153-165 1442.8 n.d.  n.d.  91.9 ± 4.6 37.0 ± 3.4 50.1 ± 6.1 0 decrease 
165-171 925.5 26.7 ± 4.1 9.39 ± 1.4 18.1 ± 2.3 7.2 ± 0.5 8.2 ± 1.3 7.3 ± 3.3 decrease 
165-192 3288.7 47.2 ± 5 13.2 ± 2.4 56.6 ± 14 20.7 ± 2.3 32.4 ± 1.9 3.0 ± 0.4 decrease 
 
 
 
For the N-terminal peptide residues 81-97 a parent peak at m/z 1819.8, there 
appeared peaks at 1835.9 and 1851.9 m/z indicating 2 oxidation events of this peptide 
upon exposure to hydroxyl radicals.  Both oxidation events were evident in the SDUF 
complex for experiment 1 but significantly decreased in relative abundance compared to 
FXN; no oxidation events were evident in the SDUF complex spectra for experiments 2 
and 3.Similarly, the peak at m/z 1855.0 corresponding to residues 148-164 on FXN had 3 
oxidation event peaks appear with exposure to hydroxyl radicals observed by the 
appearance of peaks at 1871.0, 1887.0, and 1903.0 m/z in experiments 1, 2, and 3 where 
only 2 oxidation events at 1871.0 and 1887.0 m/z at lower abundances were observed 
when FXN interacted with the SDU complex.  The peak at m/z 2011.1 corresponding to 
FXN peptide 148-165 had oxidized peaks appear at 2027.1, 2043.1, 2059.1, and 2075.1 
m/z for the FXN protein corresponding to 4 oxidation events.  When the FXN bound the 
SDU complex, peaks at m/z 2027.1 (experiments 1, 2, and 3), m/z 2043.1 (experiments 1 
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and 2), and m/z 2059.1 (experiment 1 only) appeared at lower abundances than for FXN. 
For the FXN peptide with residues 153-164 (unmodified peak at m/z 1286.7), peaks 
appeared at 1302.6, 1318.7, and 1334.7 m/z corresponding to 3 oxidation events when 
FXN was either unbound or bound to the SDU complex with lower abundances 
(experiment 2) in the SDUF complex; the peaks at 1302.6, 1318.7, and 1334.7 m/z were 
not observed in experiment 3. The peptide corresponding to FXN residues 153-165 
(unmodified peak m/z 1442.8) had peaks corresponding to 1, 2, or 3 oxidation events 
(1458.8, 1474.8, and 1490.8 m/z, respectively) appear for experiment 2 for both FXN 
and FXN in the SDUF complex and peaks corresponding to 1 or 2 oxidation events 
(1458.8 and 1474.7 m/z, respectively) were observed in experiment 3 for FXN but were 
absent for FXN in the SDUF complex. For the peptide 165-171 with an unmodified peak 
at m/z 925.5, peaks appeared at 941.4 and 957.5 m/z upon exposure to hydroxyl radicals 
in all three experiments for FXN corresponding to 2 oxidation events.  When FXN 
bound the SDU complex, both of the oxidation peaks (941.4 and 957.5 m/z) were 
observed but at a lower abundance than for FXN. The most C-terminal peptide observed 
for FXN, residues 165-192 with a peak at m/z 3288.7, showed oxidation by peaks 
appearing at 3304.6 and 3320.7 m/z corresponding to 1 or 2 oxidation events, 
respectively. When FXN bound the SDU complex, both of the peaks at m/z 3304.6 
(experiments 1, 2, and 3) and m/z 3320.7 (experiments 1 and 2) were observed at a lower 
abundance than for FXN. 
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Analysis of ISD11 in the Hydroxyl Radical Footprinting Experiments. The 
overall sequence coverage by trypsin digestion for ISD11 is shown on the protein 
sequence (Figure 2-13).  This small, mostly basic protein was not significantly modified 
through the footprinting experiments and changes in modification were not monitored 
(data not shown). The peptides identified were highlighted by black bars corresponding 
to approximately 66% of the protein sequence. 
 
 
 
Figure 2-13. The sequence coverage of ISD11 by trypsin digest from the hydroxyl 
radical footprinting experiments is shown with black bars indicating the fragments 
identified over the protein sequence. 
 
 
DISCUSSION  
The aims of this chapter were to obtain a better understanding of the interactions of 
the components of the human Fe-S assembly complex to create a model that correlates 
structure with function that can be further tested by biochemical assays.  These results 
were then used to compare the interactions of the human system to the homologous 
complex previously studied from E. coli by protein crystallography.  Previous attempts 
at protein crystallography of the NFS1-ISD11, SDU, or SDUF complexes has been 
unsuccessful and techniques such as NMR are inappropriate due to the size of the 
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complex, the amount of material required, and the challenges of producing labeled 
protein.  Therefore, a technique which requires significantly less material, is not size 
limited, and is applicable to proteins in buffered solutions was employed, namely 
hydroxyl radical footprinting. This technique covalently modifies amino acid side chains 
that are exposed to the bulk solution by oxidation from radical species.  The covalent 
modification allows for the proteins or complexes to be digested and analyzed further by 
techniques such as mass spectrometry. 
Hydroxyl radicals can be generated by various chemical means, most commonly 
through Fenton chemistry, in which Fe2+ is oxidized to Fe3+ and radicals are generated 
from H2O2 to produce hydroxide and a hydroxyl radical which can modify protein side 
chains (Figure 2-14, top panel).119-121 This reaction requires high concentrations of H2O2 
(mM), is relatively slow (minutes to modify), and is also not appropriate for metal 
binding proteins such as the SDUF complex because modification would be localized to 
the region around the metal binding site.  A second approach is to generate radicals by 
the laser photolysis of H2O2 by a KrF laser at 254nm.
122-125 This approach is attractive 
because the exposure time is on the microsecond time scale and the concentrations of 
H2O2 are much lower (µM) than required for Fenton chemistry but was not used in this 
application due to the laser requirement. Lastly, radicals can be generated from water 
molecules in buffered solutions by exposure to synchrotron radiation (Figure 2-14, lower 
panel).113, 119, 126 
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Figure 2-14. The generation of hydroxyl radicals is shown by various methods including 
Fenton chemistry (top) or the radiolysis of water by a synchrotron source (bottom). 
 
 
 
Solvent accessible side chains are susceptible to modification by hydroxyl 
radicals whereas those involved in protein tertiary structure or protein-protein 
interactions are protected from oxidation. The general reactivity of the solvent exposed 
side chains from most reactive to least reactive are as follows: Cys> Met >Trp> Tyr 
>Phe> His >Leu ~ Ile >Arg ~ Lys ~ Val >Ser ~Thr ~ Pro >Gln ~ Glu> Asp ~ 
Asn>Ala>Gly.119, 127 The oxidation reaction is quenched by the addition of a radical 
scavenger, such as methionine.112, 128 After labeling and quenching, the level of 
modification can be determined as a function of exposure time by monitoring the shift in 
peptide molecular weight by mass spectrometry after proteolytic digestion to determine 
the side chain accessibility to modification. To determine the interfaces important for 
protein-protein interactions, the proteins were labeled both individually (Figure 2-15, top 
panel) and after the assembly of the complexes (Figure 2-15, bottom panel) and the 
changes in rates of modification of a particular peptide or peptides after binding its 
 69 
 
protein partner(s) were observed.113, 115, 119, 129 The application of hydroxyl radical 
footprinting monitored by MALDI TOF mass spectrometry to understand interactions of 
a multiple protein complex, such as the SDU or SDUF complexes, which build upon a 
core protein, NFS1, is a unique application of the hydroxyl radical footprinting 
technique.  
 
 
 
 
Figure 2-15. Experimental design of hydroxyl radical footprinting showing the 
comparison between modification for the monomer (top panel) and the complex (bottom 
panel to identify the regions of protein-protein interaction. 
 
 
Many of the components of the human Fe-S cluster assembly complex have 
relatively little structural information known.  Of the four proteins, only one component 
has been crystallized, namely FXN.  In addition to structural data from NMR, the 
interactions between FXN and the SDU complex have been studied by kinetic binding 
assays indicating regions on FXN that likely interact with the SDU complex. 33, 66, 75 The 
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human system has functional differences from the homologous bacterial system, namely 
that ISD11 is required for the stability and activity of the cysteine desulfurase NFS161, 78 
and that the addition of frataxin to the SDU core activates the complex for sulfur transfer 
and enhances Fe-S cluster synthesis.33, 78  In contrast, the bacterial system does not 
contain a protein homologous to ISD11 and the cysteine desulfurase-scaffold complex 
has high cysteine desulfurase and Fe-S cluster activity that becomes diminished upon the 
addition of frataxin.78, 130Additional differences exist between the human and bacterial 
systems, such as the calculated pI of the scaffold proteins is vastly different between E. 
coli (pI 4.9) and human (pI 8.6) leading to a difference of overall charge at the pH at 
which most experiments are performed (pH ~7-7.5).  Furthermore, there exists two 
bacterial co-crystal structures of the cysteine desulfurase-scaffold complex, one from E. 
coli
31 and one from A. fulgidus, which contains one [2Fe-2S] cluster bound at the dimer 
interface.32 Despite the differences in functional activity between the human and 
bacterial systems, a strong sequence conservation exists between the components (E. coli 
IscU to human ISCU2 73%, E. coli IscS to human NFS1 59%, E. coli frataxin to human 
frataxin 24%).  The results from the hydroxyl radical footprinting experiments indicate 
that there are some structural components conserved between the bacterial and human 
systems.     
The change in oxidative modification kinetics for the N-terminus of ISCU2 
(residues 5-13) suggests that this region is protected upon forming the SDU complex 
(Figure 2-6).  Consistent with this hypothesis, an equivalent region on bacterial IscU is 
located near the protein-protein interface in crystal structures of the IscS-IscU complex 
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from E. coli and A. fulgidus.31, 32 More specifically, E. coli IscU residues Y3, Y11, G38, 
V40, K42, K59-G64, and K103 interact with IscS residues R379-K391.  Some of the 
corresponding residues (M1, Y9, G36, V38, K40, K57-62, and K101) are found in the 
N-terminal peptide 5-13 of human ISCU2, and with exception of M1 and K40, are 
highly conserved in eukaryotes.  These interactions may play a role in the disease ISCU 
myopathy with exercise intolerance if the N-terminus of ISCU2 is unable to interact with 
NFS1 based on the location of the point mutation on ISCU2 (G16E).79 
The slight protection of residues near the C-terminus of NFS1 (residues 402-419; 
two independent experiments) is consistent with the interaction of the cysteine 
desulfurase in the bacterial crystal structure of IscS-IscU (corresponding residues 379-
391 in E. coli).33, 34 The peptide residues 262-290 is not near the expected NFS1-ISCU2 
interface (Figure 2-8), suggesting this region of NFS1 may be protected due to a 
conformational change that occurs upon ISCU2 binding either on NFS1 or interactions 
with ISD11.  Together, these hydroxyl radical footprinting results may indicate 
interaction surfaces between the cysteine desulfurase to the scaffold proteins which may 
be diagnostic of conformational changes induced by complex formation.   
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A model of the human NFS1 and ISCU2 interactions was generated based on the 
E. coli crystal structure and the human protein sequences by the SWISS-MODEL 
software. The generated human model has an overall structure that is similar to its 
bacterial homologs and the interactions between NFS1 and ISCU2 as determined by the 
regions of protection from hydroxyl radical labeling are in good agreement with a 
conserved interaction (Figure 2-16A). Furthermore, when electrostatic potential maps 
were generated by the CHARMM-GUI PBEQ Solver for the human NFS1 and ISCU2 
model proteins and the regions of interaction were compared from the results of the 
hydroxyl radical footprinting experiments and were determined to be complimentary in 
charge (Figure 2-16B).  The N-terminus of ISCU2 is positively charged, displayed by 
the blue color whereas the C-terminus of NFS1 has overall negative charge, as shown by 
the red color. This model further supports the probability that NFS1 and ISCU2 interact 
in a semi-conserved manner to the bacterial system. 
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Figure 2-16. A.) A ribbon diagram of the human model of the interactions between 
NFS1 and ISCU2 is shown highlighting the peptides that were protected in the SDU 
(blue) or SDUF (cyan) complex.  The active site cysteines on ISCU2 are shown as 
yellow sticks.  B.) Electrostatic potential maps of NFS1 and ISCU2 in the same 
orientation as the ribbon diagram showing the complementary nature of the charge of the 
C-terminus of NFS1 and N-terminus of ISCU2. 
 
 
 
 
 
A. 
B. 
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Interestingly, there was one peptide on ISCU2 that appeared to be more 
susceptible to oxidation in two of the three experiments (residues 58-76, Table 2-1) in 
the SDU complex compared to ISCU2 alone in solution.  This peptide is located near the 
core of ISCU2 and the increased modification in the SDU complex indicates that this 
region became more exposed to hydroxyl radicals potentially as a result of becoming 
more unstructured upon binding NFS1-ISD11 (Figure 2-6).  The equivalent residues in 
bacterial IscU are located in the core of the αβ structure, suggesting ISCU2 has 
conformation and/or dynamic differences that expose core residues when it binds the SD 
complex. This supposition is supported by previous NMR results by the Markley group 
in which bacterial IscU was shown to exist as in equilibrium between structured and 
disordered states with the disordered state being favored to form the IscU-IscS 
complex.35 The ISCU2 peptide 58-76 was not observed in the SDUF complex, but a 
peptide corresponding to a similar region, residues 56-76 (Table 2-3, unmodified peak at 
m/z 2190.0), was observed. This peptide became slightly more modified in one 
experiment (Experiment 1) but was more protected in Experiments 2 and 3 compared to 
SDU indicating that this peptide on ISCU2 may become more structured upon formation 
of the SDUF complex, also in good agreement with the NMR results from the Markley 
lab in which they hypothesize that the disordered form of the scaffold will bind the 
cysteine desulfurase but the structured conformation is the active form for Fe-S cluster 
assembly35 and also supports a conservation of interaction between the bacterial and 
human systems. 
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In the SDUF complex, the NFS1 peptides did not show additional modification 
or protection compared to the NFS1 peptides from the SDU complex.  This void is 
probably due to the low sequence coverage (~27%) of NFS1 by peptides seen in two or 
more experiments from the hydroxyl radical footprinting experiments.  Previous studies 
in E. coli  have shown that mutations at residues R116, R220, R223, R225/E227, G234, 
R237/M239, A327, or R340 on IscS (E. coli numbering) diminish or prevent the ability 
of the cysteine desulfurase to pull down bacterial frataxin, CyaY.31 SAXS studies also 
showed that IscS residues R220, R223, R225 were important for CyaY binding.34 
Unfortunately, additional peptides that would provide information about the SDU 
complex activation upon FXN binding, specifically the mobile loop on NFS1 residues 
330-360 (based on the bacterial IscS-IscU structure) could not be evaluated because the 
peptide by trypsin digestion for residues 330-360 was not observed by the hydroxyl 
radical footprinting experiment (Figure 2-10, Table 2-4). If the interaction between 
NFS1 and FXN was conserved between the human and E. coli systems, we would have 
expected to see protection of NFS1 in corresponding regions to the IscS protein.  
The one peptide was identified on ISCU2 (residues 102-113) that became 
protected upon FXN binding to the SDU complex indicating an interaction between 
FXN and ISCU2.  The interaction to ISCU2 through this region of the protein is highly 
likely due to the accessibility for FXN based on the model generated (Figure 2-16A). 
Additionally, this peptide is near the highly conserved LPPVK motif (residues 97-101, 
human numbering) on ISCU2 which has implications in chaperone protein interactions 
for cluster transfer,52, 53 contains the highly conserved histidine (H103) which has been 
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implicated as being important for protein-protein interactions and possibly cluster 
ligation,36 a hypothesized active site cysteine (C104), and a methionine residue (M106) 
that, when mutated to isoleucine, has shown the ability to stimulate the cysteine 
desulfurase and Fe-S assembly activities of the SDU complex in the absence of 
frataxin.67, 68 The interaction between FXN and this region of ISCU2 has been further 
interrogated by mutational studies in which residues on ISCU2, K101, H103,67 and 
L107, have been mutated and showed a 10-600 fold decrease in FXN binding to the 
SDU complex (Chapter IV).  Interestingly, the ability to stimulate the cysteine 
desulfurase activity was diminished for only the H103D mutation whereas K101A, 
K101H, H103A, H103K, and L107Q were able stimulate the cysteine desulfurase 
activity to wild-type levels when the binding deficiency was overcome (Chapters IV and 
V). Mutations were also incorporated on the FXN molecule to attempt to overcome the 
binding deficiency seen with the ISCU2 mutation.  Only one complimentary mutation 
set was able to overcome the decrease in binding affinity for FXN (H103K ISCU2 with 
R165H FXN) indicating a specific interaction between histidine 103 on ISCU2 and 
arginine 165 on  FXN.67  Although binding was able to be partially recovered, the ability 
to stimulate cysteine desulfurase activity was completely destroyed indicating that the 
interaction between the binding region on ISCU2 identified by hydroxyl radical 
footprinting and FXN is vital for binding and complex activation.   
The regions on FXN that were protected in the SDUF complex determined in the 
hydroxyl radical footprinting experiments corresponded to the N-terminus (residues 81-
97) and the β-sheet region (residues 148~165) (Figure 2-4). The region of protection 
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determined by the hydroxyl radical footprinting experiments also contain many of the 
FRDA mutants which showed significantly decreased binding to the SDU complex by 
kinetic assays, specifically residues N146K, Q153A, W155R, and R165C.66, 
131Additionally, the binding constant of wild-type FXN to the SDU complex was 
determined using fluorescence anisotropy and was used to compare to the binding 
constant of the W155R FXN to the SDU complex, which was approximately 140 times 
weaker (Chapter III). Furthermore, mutations to the following FXN residues: E108K, 
E111K, D124K, N146K, W155R diminished or dissolved the ability of FXN to pull-
down NFS1, ISD11, and ISCU2 indicating a potential surface for protein-protein 
interactions as determined by Schmucker etal. This region corresponds to the residues 
spanning from the acidic ridge to the -sheet on FXN.64  Taking these results taken in 
combination indicate that it is probable that FXN interacts with ISCU2 through the β-
sheet region on FXN to the helix on ISCU2 (residues 102-113).  The electrostatic 
potential of the β-sheet region of FXN is overall neutral, with a positively charged 
pocket due to R165 (Figure 2-17) that is complimentary to the region on ISCU2 that 
showed protection (residues 102-113), which has an overall negative charge (Figure 2-
16B).  As mentioned above, the binding of FXN to the SDU complex can be recovered 
by making complimentary mutations on both FXN (R165H) and ISCU2 (H103K) but 
their specific interaction and the importance of either of these two residues to stimulate 
the cysteine desulfurase activity of the NFS1 remains to be fully understood.   
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Figure 2-17. Electrostatic potential map of FXN is shown with the acidic patch at the top 
portion of the molecule (overall negative charge, red).  The β-sheet region is shown on in 
the center of the molecule with residue arginine 165 shown (positive charge, blue).   The 
region that was protected in the hydroxyl radical footprinting experiments is neutral 
(white) to positively charged (blue) which would complement the area on ISCU2 that 
was protected in the SDUF complex (residues 102-113) which had an overall negative 
charge.  
 
 
FXN has also been shown to interact specifically with ISD11 in vivo by co-
localization experiments and in vitro by pull-down studies using FXN as the anchor 
protein.72 When the I154F mutation was incorporated on FXN, the ability of FXN to 
bind ISD11 was demolished, where the W155R FXN mutation only decreased the 
interactions of FXN to ISD11.72 This tryptophan residue that is implicated in binding to 
the SDU complex by biochemical assays75, 93 is shown as being near a positively charged 
patch of the electrostatic map (Figure 2-17).   
The peptides that were not identified on FXN corresponded to the acidic patch, 
which has previously been hypothesized to interact with the cysteine desulfurase in E 
coli.64 Although it cannot be ruled out based on the data presented here alone that there 
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is no interaction between the acidic patch on FXN and the SDU complex, the data does 
indicate that there is an interaction between the β-sheet region of FXN to NFS1.   
Lastly, the regions of NFS1 that were unmodified in the hydroxyl radical 
footprinting experiments were mapped onto the model of human NFS1 to better 
understand if these peptides were involved in the dimer interface or determine potential 
binding sites for ISD11. NFS1 was not exposed to hydroxyl radicals in the absence of 
ISD11 because NFS1 is inherently unstable in solution without its binding partner.61, 132  
The peptides on NFS1 that were identified after trypsin digestion are shown in Figure 2-
3 and 5 of the 7 peptides did not show modification in the SD, SDU, or SDUF complex 
(Figure 2-6, 2-9, Tables 2-2, 2-4).   These peptides were mapped onto the human model 
of the NFS1 dimer and this revealed that most of the region that was protected in the SD 
complex was in the dimer interface (Figure 2-18, cyan) although an additional possibility 
is that these regions were involved in interactions with ISD11 consistent with that region 
being inexcessible to hydroxyl radicals in buffer solution.  These peptides contain 
residues that have a high susceptibility to become modified,   specifically leucine (L), 
tyrosine (Y), proline (P), histdine (H), phenylalanine (F), and methionine (M) indicating 
protection rather than slower reaction conditions.133 Further, some of these regions 
appear to be highly negatively charged (red) region (Figure 2-18B), which is in good 
support of a potential surface of interaction for ISD11 due to the overall positive charge 
of ISD11 (pI ~10).  
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Figure 2-18. The regions protected on NFS1 during hydroxyl radical footprinting. A.) 
The peptides, which were not modified in the footprinting experiments, are shown in 
cyan on the NFS1 dimer (gray).  B.) Electrostatic map of the NFS1 dimer is shown in the 
same orientation as the ribbon diagram in A.  
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The results presented herein show that hydroxyl radical footprinting monitored 
by mass spectrometry was successful in identifying regions of interaction between 
NFS1, ISCU2 and FXN in the SDU and SDUF complexes.   The region of protection on 
NFS1, namely the C-terminus, is consistent with interactions observed in the bacterial 
crystal structure of the IscS-IscU complex as well as the protection of the N-terminus of 
ISCU2 indicating a conservation of interaction through evolution from bacteria to 
humans.  These experiments also identified a region on ISCU2 that has been implicated 
as being important for interactions with the cysteine desulfurase (N-terminus), 
corroborated NMR results that indicate that ISCU2 becomes more unstructured upon 
binding NFS1, and the chaperone proteins as being important for interactions with 
human FXN as well. Although a specific interaction of FXN to the SDU complex was 
not identified, the hydroxyl radical footprinting results did correctly identify the β-sheet 
region as being important for interactions as previously seen by kinetic bioassays.  The 
binding interactions of FXN to the SDU complex will be further analyzed by 
fluorescence anisotropy and the interactions of the β-sheet residue W155 will 
specifically be tested (Chapter III).   
The results also indicate that a further structural arrangement of ISCU2 or the 
SDUF complex after cluster formation, a dissociation of the cluster bound ISCU2 from 
the SDUF complex, or a dissociation of FXN after cluster formation to allow the 
chaperone proteins access to the LPPVK motif for cluster transfer would be required if 
the interaction is conserved between bacteria and humans.  The region of ISCU2 that is 
involved in these interactions (residues 102-113 by hydroxyl radical footprinting) will be 
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further analyzed by incorporating point mutations (K101, L107) to better understand the 
importance of this region for FXN binding and complex activation (Chapters IV and V).  
The importance of the N-terminus interactions of ISCU2 to NFS1 will be tested by 
incorporating the clinical mutant G16E on ISCU2 or the residues around the active site 
(D37) will be observed by monitoring the changes in binding and complex activation 
(Chapter V).  
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CHAPTER III 
DETERMINING THE BINDING CONSTANT OF NATIVE AND MUTANT 
FRATAXIN TO THE SDU COMPLEX BY USING FLUORESCENCE ANISOTROPY 
 
INTRODUCTION 
Iron-sulfur clusters are assembled by a multi-protein complex which has been 
conserved in all branches of organisms.9, 13, 16, 134 In eukaryotes, specifically humans, it 
has been discovered that four, conserved components are required for the assembly of 
Fe-S clusters.33, 64  The four required proteins for cluster assembly are a cysteine 
desulfurase (NFS1) along with its co-protein ISD11 that is responsible for the 
conversion of cysteine to alanine through a persulfide bound cysteine on NFS1.84 This 
persulfide can then be transferred to an active site cysteine on the scaffold protein named 
ISCU2 in humans.37  Frataxin (FXN) is the fourth required component and acts as an 
allosteric activator in the human system to switch the complex from an “off” state to an 
“on” state.33 The interactions of the four components of this complex are still being 
elucidated with the best model for protein-protein interactions coming from the bacterial 
system.31, 32 
Currently, the interactions of the subunits from both bacterial and human systems 
have been studied multiple biophysical techniques such as protein crystallography where 
the crystal structure of the bacterial IscS-IscU shows a C-terminal interaction of the 
cysteine desulfurase to the N-terminus of the scaffold,31, 32 and SAXS, where the 
interactions of the bacterial IscS-IscU complex formed an elongated S-shaped molecular 
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envelope.34, 64 These interactions appear to be conserved in the human system where the 
C-terminal peptide on NFS1 (residues 402-419) and the N-terminal peptide on ISCU2 
(residues 5-13) were protected from hydroxyl radicals upon SDU complex formation 
(Chapter II). Furthermore, the hydroxyl radical footprinting experiments uncovered a 
potential interaction between FXN and ISCU2 which was previously unknown (Chapter 
II) although information about protein binding kinetics were unable to be determined 
from these experiments. 
In the bacterial system, which has been studied in more detail than the human 
system, some of the binding phenomena have been elucidated.  Previously, the binding 
of IscU to IscS in E. coli was determined by surface plasmon resonance (SPR) and 
isothermal titration calorimetry (ITC) and determined the Kd to be 2.0 µM and 2.2 µM, 
respectively, approximating a 1:1 ratio.135 In good agreement with the values presented 
by Urbina et al., Prischi et al. calculated the Kd of IscS:IscU to be 1.3 ± 0.2 µM, again 
fitting the ITC data to a 1:1 binding model.34 Additionally, using a 1:1 binding model for 
the interaction between IscS:CyaY the Kd was calculated to be 18.5 ± 2.4µM.
34  
Interestingly, a direct interaction between IscU and CyaY was not observed.   
In addition to the ITC data, Prischi et al. wanted to determine if the binding of one 
component of the Fe-S cluster assembly could affect the binding of the other 
components.34  To answer these questions, the complex interactions were measured by 
biolayer interferometry (BLI) which is sensitive molecular interactions to give on and 
off interaction rates.34 When CyaY was immobilized to the surface, the binding constant 
for IscS:CyaY was determined to be 23 ± 3 µM but when IscU was added to the 
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reaction, the interaction strength increased by ~650X and the Kd decreased to 0.035 ± 
0.006 µM.34 In a similar experiment, IscS was immobilized and the Kd for IscS:IscU was 
determined to be 1.5 ± 0.3 µM but when CyaY was added to the reaction the Kd 
decreased almost four fold to 0.400 ± 0.03 µM indicating a much tighter interaction.34 
Previously, binding constants have been determined for pair-wise combinations of 
the four components of the Fe-S cluster assembly complex.136-138 Specifically, the 
binding constant for NFS1 to ISD11 in humans using surface plasmon resonance with 
ISD11 immobilized was determined to be 100 nM when fit to a 1:1 binding model.136   
The interaction of FXN to ISCU2 has been determined as a result in the change in heat 
by ITC in which Yoon et al. utilized the D37A ISCU2 variant (human numbering), 
which is known to bind a Fe-S cluster tighter as the titrant into full length or truncated, 
mature, holo human frataxin to give a Kd of 5.4 µM and 0.15µM, respectively.
37, 137, 138  
The binding constant for wild-type ISCU2 using tryptophan fluorescence quenching 
titrated with holo frataxin gave a Kd of 0.67 µM or 0.45 µM for D37A ISCU2 with holo 
frataxin.137 
The first instance of determining the binding constant of frataxin to the human SDU 
complex was determined by Bridwell-Rabb et al. using the kinetic rate constants.  In 
these experiments, the Kd was calculated based on the ability of varying concentrations 
of FXN to stimulate the cysteine desulfurase in the SDUF complex.66, 75 The Kd 
determined for native FXN to the SDU complex was determined to be 0.07 ± 0.04 µM.67 
The binding constant of many of the FRDA mutants were also determined using the 
kinetic rate constant, approach, which in all cases, the mutation to FXN caused a 
 86 
 
decrease in the ability of FXN to bind the SDU complex.  Many of these mutations are 
found on the β-sheet region of FXN (N146, Q153, W155, R165) and their decreased 
binding affinity upon mutation further supports the interactions determined by the 
hydroxyl radical footprinting results (Chapter II). This binding constant of native FXN to 
SDU is similar to the binding constant determined for IscS:IscU:CyaY from E. coli.34 
The kinetic binding assays were unable to determine the conditions in which the proteins 
formed the tightest complex due to the nature of the experiments. Therefore, it was the 
goal of this work to better understand the reaction conditions required for the 
interactions of the SDUF proteins using fluorescently labeled frataxin and observing the 
changes in fluorescence anisotropy indicating protein complex formation.  
Fluorescence anisotropy, as a technique, has been used to calculate binding constants 
between protein-DNA and protein-protein complex interactions.139-141 Briefly, 
fluorescence anisotropy is a measure the emission of a fluorophore that has been excited 
by horizontally and vertically polarized light.  The ability of the fluorescently labeled 
subunit to freely “tumble” in solution is measured as the anisotropy.139  The change in 
anisotropy is related to the change in the ability of the molecule to emit polarized light, 
which changes when the labeled molecule interacts with unlabeled molecules to form 
larger complexes.  The formation of a larger complex changes the ability of the 
fluorescently labeled protein to tumble in solution, thereby creating a difference in 
anisotropy values.  These changes in anisotropy values as a function of complex 
formation can be fit to determine the binding constant of the labeled protein.  In the 
experiments described below, the reaction conditions were modified for the SDUF 
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complex and the binding constants calculated from the anisotropy experiments were 
compared to both the previously published values calculated from kinetic rate constants 
and the rate constants determined for homologous systems in bacteria. 
 
EXPERIMENTAL PROCEDURES 
Preparation of Frataxin.  Site-directed mutagenesis (Stratagene) of the codon-
optimized frataxin gene (Δ1-55) in a pET11a vector was used to introduce a S202C 
mutation or the double mutation W155R S202C and the mutation was confirmed by 
DNA sequencing (Gene Technologies Laboratory, Texas A&M University). Each vector 
was transformed into BL21 (DE3) cells and was grown at 37 oC until an OD600 of 0.6.  
Protein expression was induced with the addition of 0.5 mM IPTG and expression 
progressed at 16 oC for 16 hours with shaking.  The recombinantly expressed protein 
was purified as previously described for wild-type.33 Native NFS1-ISD11 and ISCU2 
were expressed recombinantly and purified as previously described.33, 131 
Incorporation of Fluorophore on FXN. Purified S202C FXN or W155R S202C FXN 
was brought into an anaerobic glovebox (Mbraun, <2ppm O2) and allowed to exchange 
with nitrogen overnight. Texas Red® C2maleimide (Invitrogen) was resuspended in 
DMSO to a final concentration of 20 mM.  The fluorophore was brought into the 
glovebox and excess fluorophore was added to the FXN in 50 mM HEPES pH 7.5, 150 
mM NaCl.  The labeling was allowed to proceed for approximately 6 hours in the dark at 
~16 oC prior to dialysis aerobically against 2L of 50 mM Tris pH 7.5, 250 mM NaCl to 
remove excess fluorophore. Protein and fluorophore concentrations were calculated 
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using UV-absorbance at Abs280nm and Abs590nm(native FXN ε280= 26,030 M
-1cm-1, 
W155R FXN ε280= 20,430 M
-1cm-1and Texas Red ε590=85,000 M
-1cm-1).  The labeling 
efficiency was estimated at 80% using the ratio of protein to fluorophore concentration. 
Measurement of Cysteine Desulfurase and Fe-S Cluster Activity.  The Texas Red 
labeled FXN (FXNTX) was used to stimulate the cysteine desulfurase activity of the SDU 
complex to generate sulfide which is reacted with 20 mM N, N’-diphenyl-p- 
phenylenediamine (DPD) and 30 mM FeCl3 as previously described.
33, 66, 75 Briefly, 0.5 
µM SD, 2 mM DTT, 1.5 µM ISCU2, 5 µM Fe(NH4)2(SO4)2 and 1.5 µM FXN or FXNTX 
in 50 mM Tris pH 8.0 and 250 mM NaCl was incubated for 30 minutes in an anaerobic 
glovebox.  The reaction was initiated with the addition of 100 µM cysteine and 
incubated for 10 minutes at 37 oC before quenching the reaction with DPD and FeCl3.  
The amount methylene blue generated was determined by measuring at absorbance of 
the reaction at 670nm and the amount of sulfide was quantitated using a standard curve 
generated using Na2S. 
The ability of FXNTX to stimulate Fe-S assembly on the SDU complex was assayed 
and compared to wild-type as previously described using an Infintite M200 Pro 
microplate reader (Tecan) in an anaerobic glovebox.33, 66, 75, 78  Briefly, 8µM SD, 24µM 
ISCU2, 24 µM FXNTX, 3 mM DTT, and 200 µM Fe(NH4)2(SO4)2 was incubated for 30 
minutes in the glovebox before initiating the reaction by the addition of 100 µM cysteine 
and shaking for 10 seconds.  The absorbance was monitored at 456 nm every 30 seconds 
at 18 oC and the first 2000 seconds were used to fit the data in KaleidaGraph as 
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previously described.33, 66, 75 The reported error is the error in the fit as opposed to error 
associated with technical replicate analysis.  
Fluorescence Anisotropy Measurements. The labeled FXN, ISCU2, and SD were 
brought into the anaerobic glovebox ~12 hours prior to being used to allow them to 
exchange with nitrogen.  To initiate the experiment,  10 nM FXNTX, 10 µM ISCU2, 2 
mM DTT, and additional reagents such as Fe2+or cysteine in 50 mM Tris pH 7.5, 250 
mM NaCl were added to an anaerobic cuvette and was sealed in the glovebox prior to 
titrations outside of the glovebox.  In a separate vial, SD with 2 mM DTT was diluted in 
the same buffer as above and was sealed with a rubber septum in the anaerobic glovebox 
prior to titration. SD was titrated to FXNTX with ISCU2 using a gas tight syringe to 
prevent oxygen contamination.  Titrations with DTT alone, Fe2+, and cysteine for native 
FXNTX to the SDU complex were performed by Mr. Andrew Winn. Fluorescence 
anisotropy experiments were performed on a Fluoromax4 instrument (Horiba Jovin-
Yvon) in a 1-ml anaerobic fluorescence cuvette. Anisotropy measurements were 
collected at an emission wavelength of 610 nm after excitation at 580 nm.  The signal 
was integrated for 1 s with slits set at 5 nm each while the temperature of the cuvette was 
kept constant at 22 oC. Fluorescence anisotropy is based on the ratio between the 
detected sensitivities of the horizontally and vertically polarized light and can be 
accounted for by calculating the G factor.139  The G factor can be calculated by the 
Equation 3-1: 
 
         
   
   
      (3-1) 
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where IHV and IHH are the signals from fluorophore when excited with horizontally 
polarized light, H,  and emission observed with either vertically, V, or horizontally, H, 
aligned polarizers. The observed signals must be corrected by the G factor for the 
calculated anisotropy to be accurate.139 
As the labeled protein interacts with complex components, the fluorophore 
rotation becomes more restricted and is reflected by the change in anisotropy, which is 
measured.  The anisotropy, r, is calculated by Equation 3-2:  
 
         
        
         
                            (3-2)
  
where IVV and IVH are the signals observed when excited with vertically polarized light 
and emission is observed with the polarizers in the vertical or horizontal position, 
respectively. 139  The anisotropy of the labeled protein not interacting with its protein 
partners was observed and the anisotropy is monitored as complex components were 
titrated until there was no longer a change in signal.  The binding constant was then 
calculated by fitting the curve to the binding equation shown in Equation 3-3 in the 
KaleidaGraph software. 
 
               (
[  ]
[  ]   
)                                         (3-3) 
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where A0 and A are the anisotropy of the unbound protein and the anisotropy at a given 
titrant concentration, respectively, and the Kd is the calculated binding constant.  In the 
case of a weakly bound complex, Equation 3-3 was fit making the assumption that the 
final complex anisotropy would be the same as wild-type SDUF complex which was 
tightly bound since the mutant W155R FXNTX did not reach saturation anisotropy. The 
error associated with the anisotropy values for wild-type and W155R FXN binding to the 
SDU complex reflects the variability in the fit as opposed to error in the data for 
technical replicate analysis. 
 
RESULTS 
 Fluorescence anisotropy was used to calculate the binding constant of FXN to the 
SDU complex under different experimental conditions by incorporating a cysteine 
mutation (S202C) into native FXN, allowing for the conjugation of a maleimide-
derivative of the Texas Red® fluorophore.  This fluorophore was chosen because its 
excitation (590 nm) and emission (610 nm) wavelengths do not overlap with the spectral 
properties of the PLP cofactor, and the lifetime of the fluorophore (4.2 ns) is appropriate 
for anisotropy experiments.  Prior to the initiating binding measurements, the activity of 
the SDUF complex was measured to determine the effect of the placement of the 
fluorophore on the ability of FXNTX to stimulate the cysteine desulfurase and Fe-S 
cluster assembly activities. When FXNTX was substituted for wild-type FXN in the 
cysteine desulfurase reaction, the activity of the SDU complex was not compromised 
(Figure 3-1A) indicating the location fluorophore was not inhibiting the activity of the 
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complex. The relatively low cysteine desulfurase activity seen for the reaction with both 
the native and labeled FXN are due to batch variations in the SD protein. Additionally, 
the ability of FXNTX to stimulate the Fe-S cluster assembly was also measured using a 
plate reader in an anaerobic glovebox (Figure 3-1B). The rate of Fe-S cluster assembly 
for SDUF complex was 0.18 ± 0.01 min-1 whereas the rate for the SDUFTX complex was 
0.31 ± 0.02 min-1.  
 
 
 
Figure 3-1. The activation of the SDUF complex with fluorescently labeled FXN was 
determined and compared to the SDUF complex with native FXN. A. The activity of the 
cysteine desulfurase was monitored for wild-type SDUF (blue) and SDUFTX (magenta). 
B. Rates of Fe-S assembly were determined for SDUF (blue) and SDUFTX (magenta). 
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Measuring the Binding Constant of FXN to SDU Complex. The binding constant 
of FXN to SDU was determined under the varying conditions using the fluorescently 
labeled material.  The observed anisotropy was plotted as a function of SD titrated 
(Figure 3-2 A-D) and Kd values calculated using Equation 3-3 are shown in Table 3-1.  
All of the reactions contained 2 mM DTT in the fluorescence cuvette and also the titrant 
vial containing dilute SD to prevent protein precipitation and scattering of the 
fluorescence signal. The binding of FXNTX to SDU with DTT in the absence of cysteine 
or Fe2+was determined to be 0.55 ± 0.09 µM (Figure 5-2A, red).  Upon the addition of 
either cysteine or Fe2+ along with DTT the binding was increased another 3 to 7 fold, 
respectively (Figures 5-2B, green and 5-2C, cyan). Lastly, with the addition of both 
cysteine and Fe2+to the fluorescence cuvette prior to the SD titration, the binding 
increased approximately 11 fold compared to the binding constant with determined with 
just DTT (0.05 ± 0.01 µM, Figure 3-2D, magenta). 
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Figure 3-2. The binding graphs of FXNTX and ISCU2 titrated with SD under varying 
conditions are shown with: A). 2 mM DTT (red), B).DTT and cysteine (green), C.)DTT 
and Fe2+ (cyan), and D.)DTT, cysteine, and Fe2+(magenta). 
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Table 3-1. The calculated binding constants of native and W155R FXNTX to the SDU 
complex determined by fluorescence anisotropy and fit to equation 3-3.  **Previously 
determined binding constants by kinetic bioassays.67 
 
Complex 
Native FXNTX 
Kd (µM) 
W155R FXNTX 
Kd (µM) 
SD, ISCU2, FXNTX, 2 mM DTT 0.55 ± 0.09 5.4 ± 0.4 
SD, ISCU2, FXNTX, 2 mM DTT, 
Fe
2+
 
0.08 ± 0.03 4.6 ± 0.5 
SD, ISCU2, FXNTX, 2 mM DTT, 
cysteine 
0.20 ± 0.05 3.6 ± 0.3 
SD, ISCU2, FXNTX, 2 mM DTT, 
Fe
2+
, cysteine 
0.05 ± 0.01 5.6 ± 0.3 
SDUF (kcatKd)** 0.07 ± 0.04 5.5 ± 13 
 
 
Binding of Mutant W155R FXN to SDU. Previously, the FRDA clinical mutant 
W155R FXN located on the β-sheet region of FXN was shown to have compromised 
binding determined by kinetic rate constants.66, 67, 75To further test the accuracy of the 
fluorescence anisotropy method, W155R FXN was also labeled with the Texas Red® 
fluorophore and binding was determined in a similar manner to native FXNTX (see 
Methods). The binding of the W155R FXNTX mutant to SDU with DTT and either 
Fe2+or cysteine, or both was measured and fit to Equation 3-3 (Figure 3-3, Table 3-1).  
The anisotropy data, even at 5-10 µM SD did not reach saturation, so the data was forced 
through the maximum anisotropy value determined for the complex with native FXN.  
The results indicate that the binding of W155R FXNTX was slightly improved with the 
addition of Fe2+ or cysteine 1.2 to 1.5 fold, respectively but the addition of Fe2+ and 
cysteine did not improve the binding to the same degree as the native complex (Table 3-
1). 
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Figure 3-3. The binding of W155R FXNTX to the SDU complex was measured under 
varying conditions containing: A.) 2 mM DTT (red), B.) 2 mM DTT and cysteine 
(green), C.) 2 mM DTT and Fe2+ (cyan), or D.)2 mM DTT, cysteine, and Fe2+ (magenta). 
The data was fit to equation 3-3. 
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DISCUSSION 
 The interaction of FXN to the SDU complex was identified by the hydroxyl 
radical footprinting experiments.  The results of these experiments indicate that residues 
102-113 on ISCU2 likely interact with the β-sheet region of FXN due to the observed 
decrease in oxidation upon SDUF complex formation (Chapter II).  These experiments 
were performed in the absence of Fe2+ or cysteine and although these experiments were 
important to better understand the regions in which the proteins interact, they gave little 
information about the binding affinity of FXN to the SDU complex under different 
experimental conditions (Chapter II). Therefore, the goal of this work was to better 
understand the conditions in which the SDUF complex was the tightest bound using 
fluorescence anisotropy.  A single-site mutation was incorporated on FXN at position 
S202 to incorporate a cysteine residue to covalently attach the Texas Red® fluorophore.   
Initially, FXNTX was titrated with either ISCU2 or SD to determine whether human 
FXN would form a complex with either component in the absence of the other and these 
results indicate that FXNTX did not form a complex due to a lack in change of anisotropy 
(data not shown).  These results are in good agreement with ITC data obtained from E. 
coli in which no interaction between IscU and CyaY, the frataxin homolog was 
observed,34 but are in contrast to previously reported eukaryotic interactions, in which 
frataxin has been shown to coimmunoprecipitate with Isu2 in yeast,74 interact with a 
mutant ISCU2 protein in humans by ITC titrations,137, 138 and interact through chemical 
crosslinking.142 In E. coli, an interaction between IscS and CyaY was observed by ITC 
with a binding constant of 18.5 ± 2.4 µM and BLI binding constant of 23 ± 3 µM.34 
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Taken together, these results strengthen the postulation that all four of components of the 
Fe-S assembly complex are required to form a stable complex.33, 64 Furthermore, the 
inability of FXN to interact with SD further supports the hypothesis that there has been a 
change in the function of FXN from the simpler E.coli systems.34, 78The anisotropy data 
is in good agreement with the Kd determined by BLI in E. coli in which the binding 
strengthens approximately 660 times in the presence of IscS, IscU, and CyaY are bound 
(0.035 ± 0.006 µM) or was approximately an order of magnitude tighter by ITC than for 
the proteins in a pair-wise fashion.34 
An additional strength of using fluorescence anisotropy to determine binding 
compared to using the bioassay kinetics is the ability to test different experimental 
conditions, such as the isolated use of cysteine or Fe2+. Initial experiments determined 
that DTT was required both in the fluorescence cuvette and in the titrant to prevent 
protein precipitation and scattering of the fluorescence signal (data not shown).  The 
strength of the interaction of SDUF complex was increased with the addition of cysteine 
< Fe2+< cysteine and Fe2+ indicating that the tightest complex was formed when all of 
the components required to assemble Fe-S clusters were present (Figure 3-2D, magenta; 
Table 3-1). The calculated binding constant of the fluorescence anisotropy based on 
Equation 3-3 for the SDUF complex with Fe2+ and cysteine, 50 nM, was in good 
agreement with previously published data obtained using the kcat values in which the 
calculated binding constant was70 nM.67 
To further investigate the ability of fluorescence anisotropy to measure the binding 
of FXN to the SDU complex, a clinical FRDA mutant, W155R FXN was fluorescently 
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labeled. The binding constants obtained by the fluorescence anisotropy experiments for 
the W155R FXN were calculated using the maximum anisotropy for the wild-type FXN. 
This approach was taken because the anisotropy had not reached saturation.  By 
estimating that the final anisotropy value would be the same as for the wild-type FXN 
binding to the SDU complex, the data could be fit to equation 3-3. The W155R FXN 
mutation in humans is known to be deficient in complex binding,67, 75 activity,66 and 
have decreased stability.143-145 Furthermore, the equivalent mutation in yeast showed 
growth deficiencies74 and the ability of FXN to pull down ISD1172 or IscS and IscU was 
diminished.64 Additionally, the peptide containing the residue W155 was significantly 
protected in the SDUF complex compared to FXN as seen by hydroxyl radical 
footprinting (Chapter II) indicating that this region becomes protected from solvent in 
the SDUF complex indicating a protein interface.  
The experiments performed for wild-type FXN were repeated with W155R FXNTX 
and the Kd values are shown in Table 3-1.  The binding constant for W155R FXNTX was 
approximately 110 times weaker than native FXN to the SDU complex with DTT, 
cysteine and Fe2+. This result is similar to the Kd determined by kinetic activity in which 
the SDUFW155R complex bound approximately bound 78 times weaker than the SDUF 
complex.67 It was interesting to note that the binding was not altered significantly upon 
the addition of cysteine, Fe2+ or both cysteine and Fe2+as observed for the native 
complex.  The SDUFW155R complex is also deficient in the ability to stimulate cysteine 
desulfurase and Fe-S activity,66, 67 indicating that the SDUF complex must form prior to 
being able to generate sulfide and Fe-S clusters and that the binding and activity occur 
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sequentially as opposed to concurrently.  Additionally, it was previously postulated the 
W155R may adopt a different conformation than native FXN in which interactions are 
not favorable to interact with the SDU complex66 in support of the binding not being 
recovered by the addition of Fe2+ or cysteine as observed in the fluorescence anisotropy 
experiments. The decreased binding along with the inability of the complex interactions 
to be strengthened with the addition of cysteine or Fe2+ may be one explanation for the 
severe phenotype observed in patients with this point mutation.73  The fluorescence 
anisotropy results also support the claims that FXN interacts with SDU through the β-
sheet region as previously published34, 64, 75, 144, 146 and is further supported by the 
hydroxyl radical footprinting experiments that show a significant protection of this 
region upon SDUF complex formation (Chapter II).  The results from this chapter along 
with data from Chapter II will be used to design future experiments to test the SDUF 
complex formation. 
 Overall, the development of an approach that utilizes fluorescently labeled 
proteins to determine the binding of subunits to form the SDUF complex can be highly 
useful in further understanding the conditions necessary for the interactions of the 
individual components of this complex.  This approach is highly flexible to different 
experimental conditions and the ability of FXN to interact with mutants of ISCU2, 
NFS1, or ISD11 in future studies.  This approach is not dependent on the ability of the 
activity of the SDUF complex, which may be useful in determining binding constants 
mutant proteins that have diminished activity.  
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CHAPTER IV 
INVESTIGATING THE IMPORTANCE OF THE FRATAXIN BINDING 
INTERACTIONS TO ISCU2 ON THE ACTIVITY OF THE FE-S ASSEMBLY 
COMPLEX 
 
INTRODUCTION 
 Iron-sulfur (Fe-S) clusters are important biological cofactors involved in many 
cellular processes from DNA repair to electron transport.147, 148A complex of conserved 
proteins is responsible for sequestering and assembling Fe-S clusters in vivo.  In humans, 
the complex is composed of a cysteine desulfurase and its co-protein, NFS1 and ISD11, 
which is responsible for the catalytic conversion of cysteine to alanine through a 
persulfide bound cysteine on NFS1,149 a scaffold protein ISCU2, and frataxin (FXN) 
which acts as an allosteric activator.33 
The human ISCU2 protein serves as a scaffold for the assembly of Fe-S clusters 
prior to their delivery to biological targets and both the structure and function have been 
remarkably conserved throughout evolution (Figure 4-1).  The highly conserved LPPVK 
motif on ISCU2 (residues 97-101 using human numbering) has been implicated in being 
critical for interactions with the chaperone proteins, HscA/HscB in bacteria,52, 53 
Ssq1/Jac1 in yeast,150, 151 and human mortalin (Hsp70),152, 153 for cluster transfer to apo-
proteins in vivo. The lysine in this motif, K101 ISCU2 also appears to be important for 
interactions with a conserved glutamate on the cysteine desulfurase (Figure 4-2A) which 
is also as observed in the co-crystal structure of the E. coli IscS-IscU complex31 (Figure 
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4-2B), where the IscS subunit is shown in yellow, IscU is shown in blue, and the salt 
bridge between K103 IscU and E311 IscS (E. coli numbering) has been highlighted in 
magenta. Additionally, the importance of this interaction was observed when, in yeast, 
mutagenesis of the lysine on Isu to glutamate or alanine followed by pull-down studies 
decreased the ability to pull-down Nfs1 compared to wild-type Isu.154 The three highly 
conserved cysteine residues (C35, C61, and C104 in human numbering) are universally 
agreed to be critical for Fe-S cluster biosynthesis (Figure 4-1, blue triangles).  These 
cysteines have been proposed to be Fe-S ligands along with either H103,155, 156 C96,157 or  
conserved cysteines from a second ISCU2 molecule in a dimeric assembly.158, 159 
 
 
 
Figure 4-1. The sequence alignment of ISCU2 homologues is shown highlighting the 
conserved cysteines with blue triangles and the conserved lysine in the LPPVK motif 
with the red star. 
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Figure 4-2. A.) A portion of the cysteine desulfurase sequence alignments is shown 
highlighting the conserved glutamate that interacts with lysine of the scaffold protein by 
the red star.  B.) Crystal structure of IscS-IscU from E. coli (PDB 3LVL) with one IscS 
monomer shown in yellow and IscU shown in blue with the interaction between E311 on 
IscS and K103 on IscU shown in magenta.  The active site cysteines are also shown as 
sticks with the sulfur atoms displayed in yellow on IscU. 
 
 
 
We hypothesize that the loop on which this lysine residue, K101 is located 
undergoes a helix-to-coil transition upon complex formation to activate Fe-S cluster 
assembly similar to the conformation observed in the crystal structure of IscU from 
Aquifex aeolicus.
91 We suspect that this conformational change positions the active site 
cysteine residues on ISCU2 to accept the sulfide from the cysteine on the mobile loop on 
NFS1. Studies to determine the initial cysteine acceptor on ISCU2 have been performed 
by individually mutating the cysteine residues on ISCU2 and monitoring the transfer of 
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radiolabeled cysteine resulting in the observation that that C104 is the initial sulfur 
acceptor in the human Fe-S cluster assembly complex.67 The effect of the helix-to-coil 
transition initiated by frataxin binding to the complex has not been previously 
determined although interactions between ISCU2 and FXN were observed in the 
hydroxyl radical footprinting experiments in this region of ISCU2 (Chapter II). 
Frataxin is a conserved mitochondrial protein that interacts with the core 
components of the Fe-S cluster biosynthetic machinery and forms a multi-subunit 
complex, SDUF.64, 160, 161  Previous data indicated that FXN binding to the SDU complex 
dramatically changed the catalytic efficiency (kcat /KM) of the cysteine desulfurase from 
25 to 7900 M-1sec-1 and resulted in a 25-fold increase in the rate of Fe-S cluster 
biosynthesis.33, 160 Subsequent studies investigating the impact of substituting 
Friedreich’s ataxia (FRDA) clinical variants for the native FXN on the rates of the 
cysteine desulfurase and Fe-S cluster assembly reactions revealed that these variants 
were compromised in their binding affinity for the SDU complex and also in their 
abilities to facilitate sulfur transfer from NFS1 to ISCU2.162, 163  In the native FXN 
crystal structure, W155 is stacked above the positive charge contributed by residue 
R165.162 Consistent with this hypothesis, the crystal structure of the FRDA clinical 
R165C FXN variant revealed W155 in the proposed rotated conformation and while the 
mutant bound the SDU complex ~50 times weaker than native FXN, the kcat/KM for the 
cysteine desulfurase was nearly equivalent to that of the wild-type SDUF complex.162 
We previously hypothesized that an important component for FXN interactions 
with the SDU complex is the rotated W155 conformation.162, 163  Additionally, the β-
 105 
 
sheet region on FXN was shown to be important for protein-protein interactions to the 
SDU complex (Chapter II) and the W155R mutation was unable to bind the SDU 
complex by fluorescence anisotropy (Chapter III). We identified ISCU2 residue K101 as 
a candidate for interactions with this rotated conformation of FXN due to its 
conservation, proximity to the active site and residue C104 that is implicated as the 
primary sulfur acceptor residue during catalysis.67 
Therefore, it was the goal of this study to better understand the interactions 
between the ISCU2 and FXN in the SDUF complex by using site directed mutagenesis 
followed by kinetic bioassays.  The peptide encompassing the LPPVK motif was not 
observed in the hydroxyl radical footprinting experiments although the peptide adjacent 
to K101 did become protected upon FXN binding indicating a potential binding site for 
FXN in the SDUF complex. The results herein showed that if K101 was mutated to 
alanine or histidine the binding was significantly decreased but the ability of these 
mutants to stimulate the cysteine desulfurase activity of the SDUK101XF complex to wild 
type levels was observed suggesting that once the binding deficiency of FXN to the SDU 
complex was overcome, the activity of the complex was not affected.  In an attempt to 
better understand the interactions of two FRDA mutants to the SDU complex, the ability 
to stimulate the activity of the complex with mutations to both ISCU2 and FRDA 
mutants was observed. It was determined that the binding of FXN to the SDUK101X 
complex could not be recovered by making a complimentary mutation on FXN by 
mutating N146 to lysine.  The binding of N146K FXN was ~10 fold weaker than wild-
type and activity was also significantly impaired.  Further, the interactions of the W155R 
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FXN mutation were examined in the complex with the K101H ISCU2 mutantand the 
results showed that there was no stimulation of cysteine desulfurase activity upon the 
substitution of W155R FXN for WT in the SDUK101H complex further showing the 
importance of the W155 residue on FXN binding to the SDU complex.  The results 
presented in this chapter give further evidence of the importance of the interactions of 
ISCU2 and FXN and will serve to aid in the generation of a model to test with future 
experiments. 
 
EXPERIMENTAL PROCEDURES 
Protein Preparation and Purification. The QuikChange method (Stratagene) was 
used to introduce point mutants (K101A, K101H) into a pET11a vector containing the 
human ISCU2 gene or the point mutant (N146K, W155R) into a pET11a vector 
containing human FXN (1-55).  After DNA sequencing confirmed the mutation sites, 
K101A ISCU2, K101H ISCU2, N146K FXN, and W155R FXN were individually 
transformed into E. coli strain BL21 (DE3) cells and grown at 37C until an OD600 of 
0.6.  Expression was induced with 0.5 mM IPTG and expressed for 16C for 16 hours 
with shaking. NFS1-ISD11, ISCU2, FXN and variants were purified as previously 
described for wild-type.33 
Cysteine Desulfurase Activity of ISCU2 Variants. A previously described assay 
to detect methylene blue formation was used to determine the rate of sulfide production 
of the SDU complex as a function of ISCU2 variant concentration.33 For the titration 
reactions, assay mixtures contained 0.5 μM SD, 2 mM DTT, 50 mM Tris pH 8.0, and 
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250 mM NaCl.  ISCU2 variants were titrated to SD to determine the number of 
equivalents that saturated the cysteine desulfurase activity. Titrations of native FXN 
were then performed using the maximum amount of variant ISCU2 to determine 
maximize the activity of the SDUK101A and SDUK101H,complexes.Briefly, the standard 
assay mixture composed of 0.5 μM SD, 2 mM DTT, 50 mM Tris pH 8.0, 250 mM NaCl, 
and 5 μM Fe(NH4)2(SO4)2, maximally stimulating amounts of ISCU2 or ISCU2 variants 
determined above, and was incubated for 30 minutes with various concentrations of 
FXN in an anaerobic glovebox prior to the addition of 100 μM cysteine to initiate the 
reaction.  Similarly, the number of equivalents of mutant FXN required to maximally 
stimulate the SDU, SDUK101A or SDUK101H complexes with was determined by titrating 
N146K FXN or W155R FXN to each complex instead of native FXN. 
Determination of Michaelis-Menten Kinetics. The Michaelis-Menten kinetic 
bioassays were performed as previously described.33 Briefly, the standard assay mixture 
contained 0.5 μM SD, 2 mM DTT, 50 mM Tris pH 8.0, 250 mM NaCl, and 5 μM 
Fe(NH4)2(SO4)2 with maximally stimulating amounts of ISCU2 and FXN determined 
above and was incubated for 30 minutes in the anaerobic glovebox.  The reaction was 
initiated by the addition of cysteine and incubated anaerobically at 37 oC for prior to 
being quenched by the addition of 100 µL of each 20 mM DPD and 30 mM FeCl3. The 
formation of methylene blue was monitored by UV absorbance at 670 nm to determine 
the amount of sulfide produced by each complex. Reaction rates as a function of cysteine 
concentration (0.0125-1.0 mM) were fit to the Michaelis-Menten equation using 
KaleidaGraph (Synergy Software). 
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Binding Constant Determination of FXN Variants. The binding constant of native 
or mutant FXN to the SDU complexes with native ISCU2 or mutant ISCU2 was 
determined as previously described.67, 75  Briefly, the kcat was determined for the SDU or 
SDUK101X complexes at various FXN or mutant FXN concentrations.  The curve was fit 
to Equation 4-1 using KaleidaGraph software (Synergy Software) to solve for Kd. 
 
[    ]   
[   ]  [   ]     √ [   ]  [   ]        [   ] [   ] 
 
   (4-1) 
In the above concentration, [SDU]t is the total SDU concentrationin the assay and  
[FXN]t is the total FXN concentration.
67 
 
RESULTS 
Protein Complex Stoichiometries to Stimulate Maximum Activity. The cysteine 
desulfurase activity of the NFS1-ISD11 complex (SD) was measured as a function of 
added native ISCU2, K101A ISCU2, or K101H ISCU2variants.  The cysteine 
desulfurase activity of SD was minimized with the addition of 3 equivalents of wild-type 
ISCU2 (Figure 4-3A), consistent with published results.33  Similar to ISCU2, the 
cysteine desulfurase activity decreased with the addition of K101A with a minimization 
of activity at 100 equivalents (Figure 4-3B).  Unlike native ISCU2, the cysteine 
desulfurase activity increased as a function of added K101H ISCU2 variants and 
maximized with the addition of approximately 100 equivalents of K101H (Figure 4-3C).  
These data show that the K101 ISCU2 variants bind much weaker than wild-type 
ISCU2by the requirement of additional equivalents implying that the salt bridge formed 
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between K101 on ISCU2 and the glutamate on NFS1 is important for complex 
formation. 
 
 
 
Figure 4-3. The cysteine desulfurase activity of SD was measure to determine the 
number of equivalents of native or variant ISCU2 required for further experiments. A.) 
Cysteine desulfurase activity of SD titrated with wild-type ISCU2. B.) Cysteine 
desulfurase activity of SD titrated with K101A ISCU2. C.) SD titrated with K101H 
ISCU2. 
 
 
 
In a similar manner, FXN was titrated to the SDUK101A or SDUK101H complexes 
to determine the concentration of FXN that maximally stimulated each complex.  The 
titrations revealed that the SDUK101A and SDUK101H complexes required 40 or 50 
equivalents, respectively, to achieve maximum stimulation compared to three 
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equivalents for FXN to the native SDU complex (Figure 4-4, Table 4-1).Cysteine 
desulfurase activity levels similar to wild type (kcat9.4 0.9 min
-1) were achieved when 
saturating amounts of FXN were added to SDUK101A or SDUK101H (Table 4-1).   
 
 
 
 
 
 
Table 4-1. Kinetic parameters determined for variant ISCU2 with native and mutant 
FXN variants. *Previously reported kinetic parameters.75 ** Previously reported kinetic 
parameters. 93 
  equivalents    
ISCU2 FXN ISCU2 FXN kcat (min
-1
) KM (mM) 
kcat/KM 
(M
-1
s
-1
) 
WT WT 3 3 9.4 ± 0.9 0.022 ± 0.01 7200 ± 3000 
K101A WT 75 40 10.4 ± 0.8 0.022 ± 0.008 7800 ± 2800 
K101H WT 100 50 7.4 ± 0.6 0.008 ± 0.002 15900 ± 4800 
K101A N146K 100 50 0.70 ± 0.02 0.007 ± 0.002 530 ± 300 
K101H N146K 100 50 3.09 ± 0.06 0.0057 ± 0.0008 9000 ± 1200 
K101H W155R 100 100 n.d. n.d. n.d. 
WT N146K* 3 50 4.0 ± 0.1 0.019 ± 0.004 3500 ± 700 
WT W155R** 3 40 1.8 ± 0.1 0.013  ± 0.003 2300 ± 500 
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In an effort to determine if the charge of the lysine was also required for FXN 
binding, we used FRDA variants that have a point mutation FXN at positions N146K or 
W155R to compliment the loss of lysine on ISCU2and also determine if either of these 
residues was involved in direct interactions with K101 on ISCU2.  Titrations of N146K 
FXN to either K101A or K101H ISCU2 revealed that 50 equivalents of N146K were 
required to maximally stimulate SDUK101A or SDUK101H (Figures 4-5A and B).  Titration 
of W155R FXN to the SDUK101H complex was unable to stimulate the activity above SD 
alone even at 100 equivalents (Figure 4-5C). The ability to stimulate the cysteine 
desulfurase to wild-type levels was impaired as well, where the SDUK101AFN146K complex 
had a kcat  approximately 13 times lower than wild-type and the SDUK101HFN146K had a 
kcat ~2.5 times lower than SDUF (Table 4-1). The primary implication is that the 
mutation of K101A or K101H on ISCU2 affects the ability to form a complex with SD 
and that the K101H ISCU2 stimulates activity more similarly to wild-type ISCU2 than 
K101A ISCU2. 
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Figure 4-4. The number of equivalents of wild-type FXN required to maximally 
stimulate the cysteine desulfurase activity of the SDUK101X complexes was determined 
and compared to the wild-type SDU complex. A.) Wild-type SDU titrated with FXN. B.) 
SDUK101A titrated with FXN. C.) SDUK101H titrated with FXN. 
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Figure 4-5. The number of equivalents of mutant FXN required to maximally stimulate 
the cysteine desulfurase activity of the SDUK101A and SDUK101H complexes was 
determined. A.) SDUK101A titrated with N146K FXN. B.) SDUK101H titrated with N146K 
FXN. C.) SDUK101H titrated with W155R FXN. 
 
 
 
Kinetic Parameters for Assembly Complexes Substituted with K101X-ISCU2 
Variants and/or N146K FXN. Michaelis-Menten kinetics were determined for the native 
SDU, SDUF, SDUK101AF, SDUK101HF, SDUK101AFN146K, SDUK101HFN146K complexes 
under the conditions described above. The kcat/KM of K101A or K101H ISCU2 with 
native FXN did not decrease upon these substitutions but rather was the same as SDUF 
or increased by ~2 fold respectively (Table 4-1).  The substitution of wild-type FXN for 
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N146K FXN in the SDUK101A complex decreased the kcat/KM by ~13 fold whereas using 
N146K FXN with SDUK101H complex recovered the kcat/KM to wild-type SDUF levels 
(Table 4-1).  The kinetic parameters were not determined for the SDUK101AFW155R or 
SDUK101HFW155R complexes because no change in cysteine desulfurase activity was 
determined during the titration experiments. 
Binding Constant Determination for FXN Variants Binding to Native SDU and 
ISCU2 Variant Complexes. The binding constants were calculated by measuring the 
complex kinetics (kcat) at varying concentrations of FXN and the data were fit to 
equation 4-1. These results show that the binding constant for FXN to SDUK101A is 
decreased ~49 fold to 3.4 ± 0.7μMcompared to wild type and FXN binding to SDUK101H 
is decreased ~9 fold to 0.6 ± 0.2 μM (Figure 4-6, Table 4-2). We further speculated that 
K101 on ISCU2 interacts with residues on FXN upon binding the SDU complex.  We 
show that the decreased W155R FXN binding cannot be recovered by SDUK101H (Figure 
4-5C). The N146K FXN variant did not show a significant recovery in binding to the 
SDUK101A complex, which had a binding constant of 2.3 ± 1.9 μM (Figure 4-6C, Table 
4-2).  The binding constant of N146K FXN to the SDUK101H complex was decreased an 
additional 15 fold to 9.2 ± 4.8 μM (Figure 4-6D, Table 4-2). 
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Figure 4-6. The binding constants for FXN and FXN variants to mutant ISCU2 in the 
complex were measured kinetically by the ability to stimulate the cysteine desulfurase 
activity at varying concentrations of native or mutant FXN. A.) FXN binding to 
SDUK101A. B.) FXN binding curve to SDUK101H. C.) N146K FXN binding to SDUK101A. 
D.) N146K FXN binding to the SDUK101H complex. 
 
 
 
Table 4-2. Binding constant of FXN variants to ISCU2 variants in the SDUF complexes 
was determined kinetically. *Previously reported binding constant.67  **Previously 
reported binding constant.75 
Variant FXN Kd (M) 
ISCU2 WT FXN WT 0.07 ± 0.04* 
K101A WT 3.4 ± 0.7 
K101A N146K  2.3 ± 1.9 
K101H WT 0.6 ± 0.2 
K101H N146K  9.21 ± 4.8 
WT N146K 6.25 ± 1.40 ** 
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DISCUSSION   
There currently exists no structural model of the human interaction of between 
NFS1 and ISCU2.  The closest related results are from bacteria in which the protein 
interactions of the cysteine desulfurase and the scaffold in the Fe-S cluster assembly 
pathway have been shown crystallographically in E. coli and A. fulgidus.31, 32 It appears 
that the interaction between a conserved glutamate on IscS (E311) and lysine on IscU 
(K103, both E. coli numbering) is required for complex formation as observed was in the 
crystal structure.31 In yeast, the importance of the conserved lysine in the LPPVK motif 
on Isu was studied by mutation to an alanine or glutamate and the ability of mutated Isu 
to pull down the NFS1 was abolished.154  The results presented from the hydroxyl 
radical footprinting (Chapter II) indicate that the region on ISCU2 (residues 102-113) 
near residue K101 was protected upon FXN binding SDU to form the SDUF complex.  
Furthermore, the results of the fluorescence anisotropy experiments (Chapter III) 
indicate the importance of β-sheet residue W155R to interact with the SDU complex for 
binding. Therefore it was our intention to further probe the implications of disrupting the 
interactions between ISCU2 and FXN by designing point mutations on both ISCU2 
(K101) and the β-sheet region on FXN (N146K) to better understand the effects on 
cysteine desulfurase activity and FXN binding.  
First, we investigated a conserved ISCU2 protein residue K101 to understand its 
role in complex formation with SD. Mutation of residue lysine 101 to either alanine or 
histidine and subsequent titrations of K101A or K101H ISCU2 to SD revealed that 100 
equivalents of ISCU2 were required to minimally or maximally stimulate the cysteine 
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desulfurase activity, respectively. Thus, the substitution of K101 with either alanine or 
histidine severely disrupted the ability of ISCU2 to bind SD as expected from 
interactions observed from the crystal structure from E. coli.31 The titrations of FXN to 
the SDUK101X complexes with maximally stimulating amounts of variant ISCU2 revealed 
that 50 equivalents of FXN were required to maximally stimulate the rate of the cysteine 
desulfurase in each reaction; this value is~17 fold higher than that required for the native 
SDU complex suggesting a perturbation of the native FXN interaction to the SDU 
complex. The decreased interaction was validated by measuring the binding constant of 
FXN to the SDUK101X complexes kinetically.  FXN binding to the SDUK101A complex 
was decreased by ~49 fold compared to wild-type, whereas the binding of FXN to the 
SDUK101H complex was only decreased by ~9 fold (Table 4-2).  This result indicates that 
the imidazole ring of K101H ISCU2 may be able to partially compensate for the loss of 
lysine in the interaction between SDUK101H and FXN.  The K101A and K101H 
mutations potentially cause a shift in conformation from the helix, as seen in the crystal 
structure without frataxin, to the coil conformation preventing the tight binding of FXN 
to the SDU complex. 
We have previously identified the primary sulfur acceptor from NFS1  to ISCU2 
as residue C104 which, is on a surface exposed C-terminal alpha helix close to the 
chaperone binding LPPVK motif.67 Based on the results presented here, we propose a 
model in which ISCU2 binds NFS1 through the salt bridge formed between the lysine on 
ISCU2 and glutamate (E333) on NFS1 and proceeds to undergo a conformation change 
to allow for FXN to bind and stimulate the cysteine desulfurase activity. NMR data from 
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the Markley lab suggests two distinct conformations of the E. coli scaffold protein that 
interconvert on the millisecond time scale; we suggest these two states correspond to one 
in which the C-terminal helix housing C104 is helical and one that is coiled.  We 
hypothesize that in order for C104 to accept the persulfide sulfur from NFS1, ISCU2 
must be in the coiled conformation.  When FXN binds to the SDU complex, it stabilizes 
the coiled ISCU2 conformation and stimulates the rate of the cysteine desulfurase by 
exposing C104 to participate in the sulfur transfer reaction.   
FXN binding is accomplished by interactions of β-sheet region (residues 136-
175) to SD in the human system as observed by changes in rates of modification in the 
hydroxyl radical footprinting experiments (Chapter II) and kinetic binding experiments 
using FRDA variants.67, 93, 162 It was previously shown that the N146K mutation on FXN 
binds to the SDU complex approximately 28 times weaker than wild-type FXN.75  We 
hypothesize that this could be due to charge repulsion between the lysine on ISCU2 and 
the mutated residue on FXN.  To better address this question, we analyzed the activity of 
N146K FXN with the ISCU2 variants discussed above. We show that the 
SDUK101AFN146K complex is unable to stimulate the cysteine desulfurase and is severely 
impaired kinetically with a kcat/KM that is 14 times lower than native SDUF (Table 4-1). 
The N146K FXN binding to SDUK101A is approximately 10 times weaker than the SDUF 
complex but is nearly equal to that of the SDUK101AF complex.  The SDUK101HFN146K had 
decreased cysteine desulfurase activity by about half to SDUF but was similar to the 
SDUFN146K complex.  The kinetic activity of SDUK101HFN146K was not affected indicated 
by the fact that the kcat/KM was unaffected. The binding of N146K FXN to the SDUK101H 
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complex was ~42 times weaker than SDUF. These results taken together indicate that 
both the ability of FXN to bind and stimulate the SDU complex are integral components 
of this complex and also that the mutation at position N146K on FXN cannot be 
compensated for by making complimentary mutations on ISCU2 at position K101.  
Additional mutational studies of the hypothesized ISCU2-FXN binding region 
(residues 102-113 on ISCU2 by hydroxyl radical footprinting, Chapter II) in which 
ISCU2 was mutated at residue H103 showed that the interactions between ISCU2 and 
NFS1 were likely uninterrupted but to a lesser degree than those observed for the K101 
mutant. Mutations at residue H103 ISCU2 caused a more severe FXN binding 
phenomenon than the K101 ISCU2 mutation but the activity of complexes was 
unaffected compared to native ISCU2 in the SDUF complex. Interestingly, the binding 
of FXN to H103K ISCU2 could be partially recovered as determined by kinetic binding 
assays by incorporating a complimentary mutation on FXN at residue arginine 165 to 
histidine although the activity of the SDUH103KFR165H was unable to be recovered.
67 
Specifically, the implication is that residue K101 is more affected in binding NFS1 than 
H103 and H103 is likely involved in interactions with FXN and also in complex 
activation  possibly due to a conformational change due to its proximity to the primary 
sulfur acceptor C104.67 
The complexity of the choreography of this complex is highlighted by the ability 
of a single point mutation on ISCU2 to decrease the ability to bind NFS1 (K101) but 
also have an effect on FXN binding and complex activation. These results in this chapter 
implicate the importance of the conformation state of ISCU2 to interact with NFS1, bind 
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FXN and become activated to receive sulfur from NFS1 for cluster assembly and 
subsequent transfer to apo proteins.  It will be interesting to gain a better understanding 
of the effect on transferring intact Fe-S clusters from the K101 ISC2 variants in future 
experiments.  The interactions between ISCU2 and FXN in the context of the SDUF 
complex can be further tested by using the fluorescence anisotropy experiments outlined 
in Chapter III and doing additional mutation studies to both ISCU2 and FXN.  
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CHAPTER V 
IMPLICATIONS OF POINT MUTATIONS ON HUMAN ISCU2 TO THE IRON-
SULFUR CLUSTER BIOSYNTHESIS COMPLEX 
 
INTRODUCTION 
 The synthesis of Fe-S clusters in humans is achieved by a four protein complex 
composed of NFS1, ISD11, ISCU2, and FXN.33  The cysteine desulfurase, NFS1 and its 
co-protein ISD11 convert cysteine to alanine through the formation of a transient 
persulfide on a mobile loop cysteine on NFS1.  The sulfur can then be transferred to the 
scaffold protein, ISCU2, which will assemble Fe-S clusters with the addition of Fe2+ and 
electrons. Frataxin (FXN) functions as an allosteric activator for the Fe-S cluster 
assembly complex.33 Since Fe-S cofactors are critical for many biological processes, it is 
not surprising that there are human diseases associated with mutations in the Fe-S cluster 
biosynthetic process, including the ISCU2 and FXN components of the assembly 
complex. 
Mutations to FXN lead to the human disease Friedreich’s ataxia (FRDA), which 
is an autosomal recessive neurodegenerative disease brought on by an expanded GAA 
repeat on both FXN alleles or an expanded GAA repeat on one allele and a missense or 
nonsense mutation on the other allele.75, 164 In vitro experiments revealed that FXN 
missense mutations have decreased stability, an inability to stimulate cysteine 
desulfurase activity, and loss of Fe-S cluster assembly activity.66, 75, 143, 144  Interestingly, 
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the decreased binding and activation of FRDA variants appears to correlate to age of 
onset and severity of disease progression.75 
Mutations in the ISCU2 gene lead to a human disease known as ISCU myopathy that 
is characterized by exercise intolerance in which even trivial exercise can cause 
tachycardia and palpitations, muscle fatigue, and lactic acidosis.81  As early as 1995, 19 
patients in northern Sweden were identified with a phenotype that included decreased 
succinate dehydrogenase and aconitase activities and an overload in mitochondrial 
iron.80, 165  This phenotype has been linked to a homozygous point mutation in intron 4 
of the ISCU gene that results in the retention of a 100 base pair fragment of intron 
sequence between exons 4 and 5 in the ISCU2 mRNA; additionally, it also includes a 
premature translational stop codon in the open reading frame (Figure 5-1).81 
Consequently, the mRNA levels in muscle tissue were reduced and there appeared to be 
a decrease in translated mitochondrial ISCU2 as determined by western blot analysis.80  
This splicing defect in ISCU2 results in the disease known as myopathy with exercise 
intolerance, Swedish type.79, 81 Subsequently, a more severe disease progression was 
identified that was linked to a specific point mutation on ISCU2.79, 81 
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Figure 5-1. A schematic of the disease pathway for the ISCU2 gene that causes the 
disease myopathy with exercise intolerance is shown from the point mutation in the 
DNA to protein expression. Adapted with permission from Journal of Biol. Chem., 
287:40119-40130. Copyright 2012 American Society for Biochemistry and Molecular 
Biology.81 
 
 
 
Kollberget al. determined that such individuals contain a G>C mutation on one allele 
along with a newly identified heterozygous missense mutation on exon 3 of their second 
allele, which resulted in the conversion of a highly conserved glycine to glutamate 
(G16E) near the N-terminus of ISCU2.79  Since residues near the N-terminus are critical 
for IscU binding to IscS in bacterial systems,31 and the N-terminal residues were 
involved in protein-protein interactions as determined by hydroxyl radical footprinting 
(Chapter II, Figure 2-6), the G16E clinical variant may impact formation of the Fe-S 
assembly complex. Together, their results indicate lower ISCU2 expression is 
responsible for the ISCU2 myopathy with exercise intolerance phenotype for the 
homozygous patients but the effect of the missense mutation for the heterozygous 
patients has not been biochemically evaluated. Recently, these results were validated in 
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which the cellular effects of the G16E mutation (G50E in the publication) were 
determined in human and yeast cells for protein expression and activity.166 
NMR studies by the Markley group revealed that bacterial IscU exists as a mixture 
of structured and dynamically disordered.35, 40 Interestingly, the D37A mutation favors 
the structured state, binds IscS tighter, and contains a more tightly bound Fe-S cluster 
that evidently has slower transfer kinetics to apo targets.26, 29, 37-39 Mutational studies 
coupled to enzyme kinetics and radiolabeling experiments suggests a similar equilibrium 
between functional and non-functional states of the human SDU complex, and that FXN 
binds and stabilizes the functional form to activate the complex (Figure 5-2).78 
 
 
 
Figure 5-2. A model of the FXN based activation of a pre-equilibrium binding model of 
the SDUF complex is shown in which FXN binds an inactive form of the SDU complex 
stabilizing the complex and activating Fe-S assembly. Reprinted with permission 
Biochemistry, 51:2506-2514. Copyright 2012 American Chemical Society.78 
 
 
 
Consistent with this hypothesis, mutants of ISCU2 such as M106I were identified,68 
and biochemically verified67 that when bound to SD no longer require FXN for 
activation of the Fe-S assembly complex. Here, we test mutants predicted to stabilize the 
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structured state of ISCU2 such as D37A and L107Q (Figure 3-3, magenta), which was 
designed to hydrogen bond to the native D37 side chain, along with the G16E clinical 
mutant (Figure 5-3, cyan) in functional and binding assays.  In addition, if the initial 
hypotheses that the G16E weakens and the D37A variant strengthens binding to the SD 
complex, these variants could be useful in evaluating different super complex vs 
dissociative models for cluster transfer (Figure 1-15).  
 
 
 
Figure 5-3. IscU structure overlaid with a portion of the IscS structure. The IscU 
molecule is shown in blue with the G16E residue in cyan and the N-terminal α-helix in 
green. The active site cysteine residues are shown in orange and the D37 and L107 are 
shown in magenta. Part of the IscS molecule is shown in yellow. 
 
 
 
EXPERIMENTAL PROCEDURES 
Protein Preparation. The QuikChange method (Stratagene) was used to introduce 
the point mutations G16E, D37A, and L107Q into the human ISCU2 gene in the pET11a 
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vector.  The successful mutation was verified by DNA sequencing (Gene Technology 
Laboratory, TAMU). The resulting plasmids were individually transformed into BL21 
(DE3) E. coli competent cells.  Cells were grown at 37 oC until protein expression was 
induced at an OD600 of 0.6 with 0.5 mM IPTG and expression continued at 16 
oC 
overnight.  The mutant ISCU2 proteins were purified using the established protocol for 
wild-type human ISCU2.33  Human proteins wild-type ISCU2, FXN and NFS1/ISD11 
were purified as previous described.33 
Measurement of Cysteine Desulfurase Activity.  The cysteine desulfurase activity of 
SD was measured as a function of mutant ISCU2 concentration using a previously 
described assay.33, 66, 75  Briefly, SD (0.5 μM), mutant ISCU2, and 2 mM DTT in 50 mM 
Tris pH 7.5, 250 mM NaCl reaction buffer were incubated in an anaerobic glovebox (<2 
ppm O2) for ~30 minutes, which was maintained at 12-16 
oC before the initiation of the 
reaction with 100 μM L-cysteine.  The reactions were incubated anaerobically for 20 
minutes at 37 oC before being quenched with the addition of 100 μL of 20 mM DPD in 
7.2 M HCl and 100 μl of 30 mM FeCl3 in 1.2 M HCl. The formation of methylene blue 
was quantitated by monitoring absorbance at 670 nm.  Rates were calculated using a 
standard curve of sulfide produced from Na2S.  FXN was titrated to determine the 
amount required to maximally stimulate the cysteine desulfurase activity.  In each 800 μl 
reaction, FXN was incubated with 0.5 μM SD, mutant ISCU2, 2 mM DTT, 5 μM 
Fe(NH4)2(SO4)2 in reaction buffer for 30 minutes in an anaerobic glovebox.  The 
reaction was initiated with the addition of 100 μM L-cysteine and was incubated at 37 oC 
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in a sealed flask for 10 minutes.  The reaction was quenched, monitored at 670nm, and 
the amount of sulfide quantified as described above. 
Determination of Michaelis-Menten Kinetics. A reaction mixture of 0.5 μM SD, 2 
mM DTT, 5 μM Fe(NH4)2(SO4)2, and saturating amounts of mutant ISCU2 and FXN 
determined above was incubated for 30 minutes in the anaerobic glovebox. The reaction 
was initiated with the addition of 12.5-1000 μM L- cysteine and allowed to react for 10 
minutes at 37 oC.  The reaction rates, as a function of cysteine concentration, were fit to 
the Michaelis-Menten equation using KaleidaGraph (Synergy Software). 
Binding Constant Determination of FXN with Mutant ISCU2 to the Complex. The 
binding constant of FXN to the SDUG16E, SDUD37A, or SDUL107Q complex was 
performed as previously described.66, 75  The kcat of each reaction as a function of [FXN] 
was fit to a modified quadratic interpretation of the Michaelis-Menten equation in 
KaleidaGraph to calculate the Kd of FXN binding using equation 4-1 previously 
described.67 
Iron-Sulfur Cluster Assembly Assay.  The ability of the mutant ISCU2 to assemble 
Fe-S clusters was assayed and compared to wild-type as previously described using 
maximally stimulating amounts of mutant ISCU2 and FXN anaerobically either in a 
sealed UV-Vis cuvette or on a Tecan microplate reader which was in an anaerobic 
glovebox.33, 66, 75, 78 
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RESULTS 
 The Effect of G16E ISCU2 to the SDU and SDUF Complexes.  The effect of 
G16E ISCU2 binding to SD was monitored by the change in cysteine desulfurase 
activity upon G16E ISCU2 titration.  The activity of the SD complex is minimized upon 
the addition of 3 equivalents of wild type ISCU2 (Figure 5-4A). The cysteine 
desulfurase activity upon G16E ISCU2 titration did not decrease as significantly as for 
wild-type even at 100 equivalents (Figure 5-4B). The error bars represent the average 
activity of three independent titrations. Therefore, for further experimentation, 80 
equivalents of G16E ISCU2 were used to determine the maximum cysteine desulfurase 
activity upon the titration of native FXN. The maximum stimulation of the SDUG16E 
activity was achieved at approximately 60 equivalents of FXN (5-4C). The titration, with 
additional equivalents of ISCU2G16E and FXN, did not affect the rate cysteine 
desulfurase activity.   
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Figure 5-4. Cysteine desulfurase activity of SD with G16E ISCU2 monitored as a 
function of methylene blue formation at 670 nm.  A.) Cysteine desulfurase activity of 
SD as a function of equivalents of native ISCU2. B.) The clinical mutant G16E ISCU2 
titrated into SD to determine the effect on cysteine desulfurase activity with SD alone. 
C). Titration of FXN to SDUG16E to determine maximum stimulation of cysteine 
desulfurase activity. 
 
 
 
 
 
 
C. 
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Cysteine Desulfurase Activity of the SDUG16EF Complex. The maximally stimulating 
amounts of G16E ISCU2 and FXN determined above were used to measure the 
Michaelis-Menten kinetics of the SDUG16EF complex (Figure 5-5).  Upon comparison to 
the wild-type SDUF complex, the activity of the mutant SDUG16EF complex was not 
compromised (Table 5-1). 
 
 
 
Figure 5-5. Michaelis-Menten kinetics were determined for the SDUG16EF complex using 
80 equivalents of G16E ISCU2 and 60 equivalents of FXN.  The rate was fit in 
KaleidaGraph. 
 
 
Table 5-1. Kinetic parameters for determined the clinical mutant ISCU2G16E complex. 
*Previously published binding constant for the native SDUF complex.67 
Complex 
kcat 
(min
-1
) 
KM
Cys 
(mM) 
kcat/KM 
(M
-1
s
-1
) 
Kd 
(µM) 
SDUF 11.0 ±  1 0.021 ± 0.009 8,700 ± 3,800 0.07 ± 0.04* 
SDUG16EF 7.2 ± 0.4 0.011 ±0.003 10,900 ± 3,000 2.7 ± 0.6 
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Determining the Binding Constant of FXN to SDUG16E.  The effect of FXN 
binding to the SDU complex with the clinical mutant G16E ISCU2 was determined 
using the cysteine desulfurase activity assay where the rate was plotted as a function of 
the concentration of FXN and the Kd was calculated (Figure 5-6) and compared to wild-
type SDUF based on Equation 4-1.66, 75  Frataxin binds the SDUG16E complex 
approximately 40 times weaker than the native SDU complex (Table 5-1). 
 
 
Figure 5-6. The binding constant was measured for FXN to SDUG16E as a function of 
[FXN] and measured kcat values.  The Kd was fit to Equation 4-1 in KaleidaGraph. 
 
 
 
Iron- Sulfur Cluster Assembly Assay. The ability of the SDUG16EF complex to 
turn over Fe-S clusters was determined by monitoring the absorbance at 456 nm, typical 
for [2Fe-2S], as a function of time and the curve was fit to first order kinetics. 
Maximally stimulating amounts of G16E ISCU2 and FXN were used and the rate was 
compared to the wild-type SDUF complex (Figure 5-7).The rate of Fe-S cluster 
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assembly for the native SDUF complex was 0.45 ± 0.02 min-1 (Figure 5-7, blue) 
compared to the SDUG16EF complex which was slightly compromised in activity at a rate 
of 0.35 ± 0.04 min-1 (Figure 5-7, cyan). 
 
 
 
Figure 5-7. Iron sulfur cluster assembly of SDUF and SDUG16EF.  The rate of Fe-S 
cluster assembly was monitored as a function of time at 456 nm for SDUF (blue, 0.45 ± 
0.02 min-1), andSDUG16EF (cyan, 0.35 ± 0.04 min
-1). 
 
 
 
 Effects of the Stability of Mutant ISCU2 to Stimulate Cysteine Desulfurase 
Activity. The ability of the D37A or L107Q ISCU2 to decrease the cysteine desulfurase 
activity of SD was determined (Figure 5-8A) and compared to wild-type (Figure 5-1A).   
There was no noticeable change in the cysteine desulfurase activity when D37A ISCU2 
was titrated (Figure 5-8A, orange) to SD. When L107Q ISCU2 was titrated, a similar 
trend to wild type, a decrease in SD activity, was observed (Figure 5-8 A, green). From 
these curves, further experiments were performed with 30 equivalents ISCU2D37A and 20 
equivalents ISCU2L107Q.  
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 The amount of FXN required to maximally stimulate the SDUF complex with the 
mutant ISCU2 was determined by titrating FXN to the mutant SDU complex using the 
amount of ISCU2 determined above (Figure 5-8B).  Both mutants were able to fully 
stimulate the cysteine desulfurase activity to wild type levels with the addition of either 
10X FXN or 20X FXN for SDUD37A or SDUL107Q, respectively. Additional equivalents 
of D37A ISCU, L107Q ISCU2, or FXN did not further affect the rate of cysteine 
desulfurase activity. 
 
 
 
 
Figure 5-8. The cysteine desulfurase activity stimulated with ISCU2 mutants D37A and 
L107Q. A.) Cysteine desulfurase activity of SD with mutant ISCU2 titrated (orange 
D37A; green L107Q). B.) Cysteine desulfurase activity of SDUmutant with FXN titrated 
(colors the same as in A). 
 
  
Determination of Michaelis-Menten Kinetics for the SDUmutantF Complexes. The 
Michaelis-Menten kinetics were determined for the maximally stimulating amounts of 
D37A ISCU2 or L107Q ISCU2 and FXN determined above as above and the rate of 
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cysteine desulfurase activity as a function of cysteine concentration was plotted to 
determine the kcat (min
-1) and KM (mM) for each complex (Figure 5-9).  The SDUD37AF 
or SDUL107QF complex was not compromised it its cysteine desulfurase activity 
compared to wild type when maximally stimulating amounts of either D37A ISCU2 or 
L107Q ISCU and FXN were used (Table 5-2). 
 
 
 
Figure 5-9. The Michaelis-Menten kinetics of SDUmutantF  complex with ISCU2 mutants 
A.) D37A and B.) L107Q were measured using maximally stimulating amounts of 
mutant ISCU2 and FXN. 
 
 
 
Table 5-2. Kinetic parameters determined for the SDUD37AF and SDUL107QF complexes. 
Complex 
kcat 
(min
-1
) 
KM
Cys 
(mM) 
kcat/KM 
(M
-1
s
-1
) 
Fe-S assembly rate 
(min
-1
) 
SDUF 11.0 ±  1 0.021 ± 0.009 8,700 ± 3,800 0.168 ± 0.008 
SDUD37AF 8.7 ± 0.7 0.016 ±0.006 9,300 ± 3,000 0.38 ± 0.05 
SDUL107QF 12.0 ± 1 0.022 ± 0.009 9,000 ± 4,000 0.19 ± 0.02 
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Iron Sulfur Cluster Assembly with Mutant ISCU2 Protein. The ability of the 
mutant ISCU2 proteins in the SDUF complex to assemble Fe-S clusters was interrogated 
by monitoring the increase in absorbance at 456nm which is typical for 2Fe-2S 
clustersas a function of time.  The cluster assembly was determined using 30X D37A 
ISCU2 and 10X FXN or 20X L107Q ISCU2 and 20X FXN (Figure 5-10).  The Fe-S 
cluster assembly rates for wild type SDUF, SDUD37AF and SDUL107QF were fit to first 
order kinetics and compared to native SDUF (Table 5-3). These results show that the 
rate of Fe-S cluster assembly with the L107Q ISCU2 is similar to wild-type whereas the 
rate is almost twice that of the SDUF complex.  
 
 
Figure 5-10. Fe-S assembly kinetics measured of the ISCU2 mutants D37A and L107Q 
in the  A.) wild-type SDUF, B.) SDUD37AF, or C.) SDUL107QF complexes. 
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DISCUSSION 
The clinical mutation of the highly conserved glycine at residue 16 (human 
numbering) to glutamate on the scaffold protein ISCU2 has been identified as being the 
cause of myopathy with exercise intolerance, Swedish type.  The location of the glycine 
in the native peptide is on a flexible linker between the N-terminal α-helix (residues 1-
11) and the first β- sheet and mutation may cause a decrease the binding to the 
NFS1/ISD11 (SD) complex.31 The unpublished NMR structure of ISCU2 from Mus 
musculus (PDB 1WFZ) indicates this region of the protein is highly flexible and 
unstructured loop. Examination of the human ISCU2 homolog structure from E. coli 
revealed the native glycine residue at position 16 (human numbering) is in a forbidden 
region of the Ramachandran plot, and suggests that the G16E mutation may adopt a 
different main-chain conformation and perturb the N-terminal region of ISCU2.  The N-
terminal region of the E. coli IscU structure is known to interact with IscS  as determined 
by deletion mutagenesis coupled to pull-down studies, which indicated IscU residues 1-6 
have minor contribution in binding IscS, whereas deletion of residues 1-12 or 1-17 
completely abolished binding.31 Although we suspect that the G16E ISCU2 mutation 
may weaken its binding to the SD complex, its functional properties have not been 
evaluated.  Additionally, frataxin binding to the IscS-IscU complex in E. coli has been 
shown to increase the binding of IscU to IscS.34  This trend was also observed in the 
hydroxyl radical footprinting experiments in which the peptides that were protected in 
the SDU complex underwent further protection upon the addition of FXN indicating a 
more tightly bound complex was formed (Chapter II).  How the clinical mutation on 
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human ISCU2 affected FXN binding the SDU complex was also determined using 
previously established biochemical kinetic assays.66, 75 
 First, we aimed to determine if the binding of G16E ISCU2 to the NFS1/ISD11 
complex was affected by monitoring the change in cysteine desulfurase activity upon 
mutant ISCU2 titration. The results presented are in good agreement with the hypothesis 
that the glutamate is unable to adopt the same conformation as the native protein with 
glycine at this position by the requirement of 80 equivalents of G16E ISCU2. This 
mutation, in turn, likely affects the ability of the N-terminus of G16E ISCU2 to adopt the 
correct conformation to make important interactions with SD, which were also observed 
from the hydroxyl radical footprinting experiments. Furthermore, the binding of FXN to 
the SDUG16E complex was approximately 40 times weaker than FXN to the native 
SDU complex (Table 5-1).  The weaker binding of FXN could be due to the flexible N-
terminus of G16E ISCU2 adopting a conformation that is not preferential to FXN 
binding. The importance of the N-terminus of ISCU2 to interact with NFS1 has been 
previously determined by pull-down studies in which truncation of the N-terminus loses 
the ability to pull down IscS.31 Furthermore, the G16E ISCU2 mutation in yeast loses the 
ability to interact with human NFS1 or yeast Nfs1.166  
 Furthermore, the combination of the lower expression of G16E ISCU2 protein in 
patients with myopathy with exercise intolerance80, 166 and compromised binding of FXN 
to the SDUG16E complex can be used to correlate the phenotypes observed with the 
biochemical results presented here.  The slight decrease in Fe-S clusters assembly could 
lead to an iron overload, which was is consistent with the increase in iron by 
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histochemical staining and electron microscopy.79  The combination of decreased 
expression levels G16E ISCU2 protein and decreased FXN binding might be able to 
explain the decrease in aconitase, succinate dehydrogenase and cytochrome oxidate 
activities seen previously79, 80, 165 by lower amounts of Fe-S clusters being 
synthesized..In vivo human and yeast cell studies showed that the activity of aconitase, a 
down-stream acceptor of Fe-S clusters, was compromised, the cell viability decreased, 
and there was an increase in iron content and reactive oxygen species for the cells 
containing the G16E mutation (G50E in the manuscript) compared to cells containing 
native ISCU2.166 In contrast to that work, the wild-type activity levels were obtained 
using the SDUG16EF complex once the binding deficiencies were overcome (Table 5-1) 
indicating that the activity of the G16E ISCU2 mutant does not compromise the cysteine 
desulfurase activity (Figure 5-5) and only slightly affects Fe-S assembly activity (Figure 
5-7). This result would presume that the mutation does not affect the active site of the 
scaffold protein but that deficiencies observed in vivo are likely due to a decrease in 
mutant scaffold protein expression, decreased interactions with the cysteine desulfurase, 
and the diminished ability of FXN to bind and stimulate the SDUF complex. 
Additionally, a D37A (human numbering) point mutation on ISCU2 was 
discovered in NifU, a bacterial homolog to ISCU2, in which the Fe-S cluster is more 
stably bound than in the native protein and exhibits inhibited cluster transfer kinetics.26, 
29, 37-39  UV-Vis and Mössbauer spectroscopy of the human ISCU2 D37A variant 
revealed a [2Fe-2S]2+.37 The role of this aspartate has been hypothesized: (1) to function 
as a cluster binding ligand; and (2) in charge destabilization of this region of the protein 
 139 
 
structure to labilize the cluster for transfer to apo-target proteins.37  NMR spectroscopy 
and thermal stability assays indicate the D39A IscU (E. coli numbering) is more 
structured than wild-type and binds IscS tighter.32, 35, 40  The effects of the D37A and also 
L107Q point mutation on ISCU2 on the cysteine desulfurase and Fe-S cluster assembly 
were determined using previously described biochemical kinetic assays.66, 75 
Introducing the D37A or L107Q point mutation on ISCU2 did not have as 
pronounced of an effect upon binding SD as the G16E mutation as they only required 30 
or 20 equivalents, respectively (Figure 5-8A). Additionally, both required fewer 
equivalents of FXN than the G16E ISCU2 protein to fully stimulate the cysteine 
desulfurase (Figure 5-8B). Taken together, these results indicate that there was a larger 
structural perturbation upon introducing the G16E mutation than either the D37A or 
L107Q mutation which affected not only interactions with SD but also interactions with 
FXN. The SDUD37AF and SDUL107QF complexes were not compromised in their ability 
to stimulate the cysteine desulfurase if additional equivalents of both mutant ISCU2 and 
FXN compared to wild-type were added to the assay. Furthermore, the SDUL107QF 
complex was not compromised in its ability to assemble Fe-S clusters.  
Interestingly, there was a difference in Fe-S cluster assembly rate from wild-type 
for the SDUD37AF complex. The SDUD37AF complex assembled Fe-S clusters at twice the 
rate of the wild-type SDUF complex.  The overall change in absorbance was only 
approximately half indicating that although the cluster may assemble faster, the total 
number of Fe-S clusters assembled was less than wild-type potentially implying that the 
cluster is retained on the complex and is not lost in solution, allowing fewer turnovers. 
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Therefore, it will be important to determine if, once the cluster is assembled, there is a 
difference in rate of transfer to apo target proteins.  The functional biochemical studies 
show that once binding is overcome, the SDUD37A and SDUL107Q complexes can be 
stabilized by FXN and the cysteine desulfurase activity is not affected and the Fe-S 
cluster assembly is not compromised for the SDUL107QF complex. 
The amino acid leucine 107 was included on a peptide on ISCU2 that was 
protected in the SDUF complex by hydroxyl radical footprinting (Chapter II) in the 
SDUF complex and is adjacent to residue M106 which has been shown to be able to 
recover activity due to FXN deficiency in both humans and yeast.67, 68  It was interesting 
to note by the results in this chapter that substitutions at L107 that the cysteine 
desulfurase and Fe-S assembly activities were not affected and it appears that the FXN 
binding is only minimally decreased although the cysteine desulfurase activity in the 
absence of FXN was not recovered by this particular mutation indicating that single 
amino acid exchange from methionine to isoleucine at position 106 has some functional 
as well as potentially structural effect in stimulating the cysteine desulfurase protein.   
Future studies to better understand the binding phenomena of FXN to the SDU 
complex with ISCU2 active site variants, similar to the fluorescence anisotropy 
experiments described in Chapter III, would be necessary to fully understand the 
implications of making active site mutation to ISCU2 in the SDUF complex.  In addition 
to deeper understanding of binding phenomena, the ability of these mutant ISCU2 
proteins to interact with the chaperone proteins and transfer the cluster to apo proteins 
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will be useful to fully understand the importance of these mutations to the active site of 
ISCU2. 
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CHAPTER VI 
CONCLUSIONS 
 
 The studies presented here give insight into the protein-protein interactions of the 
four proteins involved in iron sulfur cluster assembly in humans.  The data collected and 
analyzed in this dissertation was then compared to the available data from the highly 
homologous bacterial system, which is much more thoroughly studied than the human 
system to date. A multidimensional approach that was applied allowed for the complex 
to be studied structurally in solution by hydroxyl radical footprinting and fluorescence 
anisotropy but also kinetically by introducing point mutations and observing the changes 
in the ability of the complex to stimulate the cysteine desulfurase and Fe-S cluster 
assembly assays and determine binding constants. The data taken in combination leads 
toward a better understanding of the interactions of this complex and their implications 
in the diseases associated with mutations to their components, namely Friedreich’s 
Ataxia and ISCU myopathy with exercise intolerance. 
Initially, hydroxyl radical footprinting experiments were designed to understand 
how the proteins interacted since more popularized techniques such as protein 
crystallography and NMR analysis were not successful. The results presented in Chapter 
II uncovered a region on NFS1 (C-terminus, residues 402-419) that interacted with 
ISCU2 (N-terminus, residues 5-13) in the SDU complex and a region on ISCU2 that was 
protected in the SDUF complex (residues 102-113).  The C-terminal to N-terminal 
interaction of the NFS1 protein to ISCU2 has been previously observed in the bacterial 
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systems31, 32 and leads to the hypothesis that this particular interaction is conserved 
through evolution.  Additionally, a region on ISCU2 was identified as becoming 
protected upon FXN binding the SDU complex, residues 102-113 as well as protection 
of FXN on the β-sheet region of the protein.  The results indicated a potential site of 
interaction for ISCU2 and FXN in the SDUF complex and further supported the 
hypothesis the FXN interacts with the SDU complex through the β-sheet region.66, 75 
The interactions of FXN to the SDU complex were further studied by 
fluorescence anisotropy to measure the binding constant of native and W155R FXN, a 
mutation seen in some instances of FRDA.  These results showed that the binding 
constants determined by biochemical kinetic assays were consistent with the values 
determined using fluorescence anisotropy, that the binding of FXN could be determined 
under various conditions and that the tightest binding complex was obtained when all of 
the components required for Fe-S cluster assembly were present (Chapter III).  Further, 
the inability of the W155R FXN mutation to form a stable complex was highlighted by 
the inability to increase binding upon the addition of Fe2+ or cysteine indicating the 
importance of this residue in protein-protein interactions. 
 The results presented in chapters 2 and 3 were further studied by incorporating a 
point mutation on ISCU2 (K101) near the hypothesized FXN binding region uncovered 
by the hydroxyl radical footprinting to determine the effects kinetically (Chapter IV).  
The K101 mutation on ISCU2 had a decreased affinity to bind NFS1 and subsequently 
FXN but the activity was not compromised after the binding was compensated for 
indicating that perturbations to this region of the protein have a larger impact on binding. 
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A point mutation on FXN was designed (N146K) to attempt to compensate for the 
decreased binding of native FXN to the SDUK101X complexes but was unsuccessful in 
recovering binding and furthermore, showed a decrease in activity for the 
SDUK101AFN146K complex.  Therefore, it has been hypothesized that the combination of 
the K101A ISCU2 and N146K FXN mutation changes the environment on the SDUF 
complex that is required for sulfide transfer and that conformational state of the complex 
is vital for activity.   
 Lastly, to test effects of the ISCU2 clinical mutant on the activity of the SDUF 
complex, the G16E ISCU2 mutation was introduced and the ability of this mutant to 
stimulate cysteine desulfurase and Fe-S assembly activities was determined (Chapter V).  
Additionally, the ability of FXN to bind the SDUG16E complex was determined.  The 
results of these experiments indicate that the G16E ISCU2 protein likely binds less 
tightly with NFS1 and therefore FXN does not bind as tightly.  These results are 
consistent with the results of the hydroxyl radical footprinting experiments (Chapter II), 
which determined that the N-terminus of ISCU2 interacts with NFS1.  The glutamate 
substitution at position 16 on ISCU2 likely prevents the N-terminus from adopting the 
correct conformation to interact with NFS1 similar to the native protein.  The activity of 
the SDUG16EF complex was slightly decreased in Fe-S assembly activity likely due to the 
decreased binding of FXN.  We determined that the activity of the complex was not 
compromised with the introduction of mutations near the active site.   
Future studies are required to determine the effects of FXN binding when active 
site mutations are introduced on ISCU2 and the conditions in which Fe-S cluster transfer 
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occurs to apo target proteins and determine the stability of the SDUF complex upon Fe-S 
cluster transfer. The rate of transfer for intact Fe-S clusters in both the wild-type SDUF 
and also the SDUD37AF complexes will give further insight to the effect of 
structure/disorder of ISCU2 and the role of this conserved aspartate in cluster assembly 
and transfer.  Additionally, a newly determined regions of interest on NFS1 (residues 
262-290) and ISCU2 (residues 102-113) were observed the implications of additional 
mutations to these regions can be tested. The results presented in this dissertation show 
the utility of previously unused techniques to uncover protein-protein interactions of 
large heteroprotein complexes.  Furthermore, fluorescence anisotropy experimental 
protocols were established in which the binding constant of fluorescently labeled protein 
can quickly be determined using low protein concentrations for subunits to the complex.  
The regions of interactions determined by the hydroxyl radical footprinting and 
fluorescence anisotropy experiments were further validated by using the kinetic 
bioassays previously established in our lab and the results have led to additional testable 
hypotheses. 
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APPENDIX A 
MASS SPECTRA USED TO GENERATE RATE CURVES TO DETERMINE 
PROTEIN-PROTEIN INTERACTIONS 
 
 The figures contained within in this appendix are the mass spectra used to 
generate the rate curves in Figure 2-5, Figure 2-6, Figure 2-8, Figure 2-9, and Figure 2-
10.  The mass spectra were collected on an Applied Biosystems 4800 MALDI TOF/TOF 
mass spectrometer and analyzed using Data Analysis software.  The relative abundance 
of the peaks shown was used to calculate the percent unmodified (Equation 2-1), which 
was then used to determine the rate of modification for a particular peptide (Equation 2-
2).  
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A-1. Mass spectra from ISCU2, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-2. Mass spectra from SDU, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-3. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-4. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-5. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-6. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-7. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-8. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-9. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-10. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-11. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-12. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-13. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-14. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-15. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-16. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-17. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-18. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-19. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-20. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-21. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-22. Mass spectra from SDU, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-23. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-24. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-25. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-26. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-27. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-28. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-29. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-30. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-31. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-32. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-33. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-34. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-35. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-36. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-37. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-38. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-39. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-40. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-41. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-42. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-43. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-44. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-45. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-46. Mass spectra from ISCU2, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-47. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-48. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-49. Mass spectra from ISCU2, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-50. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-51. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-52. Mass spectra from SD, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-53. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-54. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-55. Mass spectra from SD, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-56. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-57. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-58. Mass spectra from SD, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-59. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-60. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-61. Mass spectra from SD, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-62. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-63. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-64. Mass spectra from SD, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-65. Mass spectra from SDU, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-66. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-67. Mass spectra from SD, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-68. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-69. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A70. Mass spectra from NFS1, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-71. Mass spectra from SDU, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-72. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-73. Mass spectra from NFS1, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-74. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-75. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-76. Mass spectra from NFS1, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-77. Mass spectra from SDU, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-78. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-79. Mass spectra from NFS1, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-80. Mass spectra from SDU, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-81. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-82. Mass spectra from FXN, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-83. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-84. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-85. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-86. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-87. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-88. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-89. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-90. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-91. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-92. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-93. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-94. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-95. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-96. Mass spectra from FXN, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-97. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals.  The peaks at m/z 920.42 and 933.55 are from ISD11. 
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A-98. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals.   
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A-99. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals.  The peaks at m/z 920.43 and 933.56 are from ISD11. 
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A-100. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals.   
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A-101. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals.  The peaks at m/z 920.42 and 933.55 are from ISD11. 
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A-102. Mass spectra from FXN, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-103. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-104. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-105. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-106. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
 272 
 
 
A-107. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-108. Mass spectra from FXN, Experiment 1 at various exposure time to hydroxyl 
radicals. 
 274 
 
 
A-109. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-110. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-111. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-112. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-113. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-114. Mass spectra from FXN, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-115. Mass spectra from SDUF, Experiment 1 at various exposure time to hydroxyl 
radicals. 
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A-116. Mass spectra from FXN, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-117. Mass spectra from SDUF, Experiment 2 at various exposure time to hydroxyl 
radicals. 
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A-118. Mass spectra from FXN, Experiment 3 at various exposure time to hydroxyl 
radicals. 
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A-119. Mass spectra from SDUF, Experiment 3 at various exposure time to hydroxyl 
radicals. 
 
